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ABSTRACT

PROGESTERONE REGULATION OF INSULIN LIKE-GROWTH FACTOR
BINDING PROTEIN-5 GENE TRANSCRIPTION IN HUMAN OSTEOBLASTS
by
Viroj Boonyaratanakornicit

Insulin-like growth factor binding protein-5 (IGFBP-5) is produced by osteoblasts
and potentiates IGF mitogenic actions in osteoblast cultures. Progesterone (PG) increases
osteoblast proliferation and increases osteoblast IGFBP-5 expression. Mechanisms
underlying PG induction of IGFI3P-5 expression were investigated in U2 human
osteosarcoma cells. In nuclear run-on analyses, PG increased IGF)3P-5 gene transcription
to 400% of control. To define the underlying mechanisms, the human IGF13P-5 gene
proximal promoter was cloned and sequenced. The proximal 500 bp of this region
contains TATA and CAAT boxes, five putative PG response element (PRE) half-sites
and two tandem CACCC boxes. Chloramphenicol acetyltransferase (CAT) reporter
constructs containing up to 753 bp of the human IGFBP-5 gene 5'-flanking sequence
were made. In U2 cells transfected with reporter construct pCAT753 containing positions
-753 to t23, PG increased CAT activity to 134% of untreated control activity (P<0.01).
Cotransfection with a PG receptor isofonn A (PR-A), but not PR-B, expression vector
increased PG induction of CAT activity to 200-300% of control (cells with vector alone •

and no PG treatment). Deletion analysis of the human IGFBP-5 promoter indicates that
PG induction of IGFBP-5 gene transcription does not require the PRE half-sites but does
require the region from -162 to -124 containing tandem CACCC box sequences.
Mutation of the proximal CACCC box at -139 eliminated PG induction of CAT
expression. Gel shift analysis using a -162 to -124 DNA fragment, U2 cell nuclear
extracts and purified PR proteins indicates that nuclear factors bind to the proximal
CACCC sequence at -139, and that PR-A (but not PR-B) alters the pattern of
transcription factor interaction with CACCC sequences. Results suggest that PG may
stimulate human IGFBP-5 transcription via a novel mechanism involving the interaction
of PR-A and CACCC binding factors.
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CHAPTER ONE
I. INTRODUCTION
A. Bone Metabolism
Bone is not metabolically inert, in fact, it is in a constant state of turnover, in
which old bone is being replaced by newbone. The processes of bone turnover and
remodeling include bone resorption and formation and occur mainly at the endosteal bone
surface (the internal bone surface which has contact with bone marrow) (Jee, 1983). Two
types of cells are critical to bone resorption and formation: 1) bone resorbing cells,
osteoclasts, which demineralize bone and digest collagen and noncollagen proteins of the
bone matrix, and 2) bone forming cells, osteoblasts which synthesize and mineralize the
bone matrix.
1. Osteoclast
Osteoclasts are unique and highly specialized cells. They arise from
hematopoietic mononuclear cells in the bone marrow (Roodman et al., 1985). The most
likely stem cell from which osteoclast is formed is a colony forming cell for the
granulocyte-macrophage series (CFU-GM) (Scheven et al., 1983). Osteoclasts are
formed by the fusion of precusors on or near the bone surface resulting in large
multinuleated cells. Osteoclasts contain lysosomes, nonuniform or pleomorphic
mitochondria, and a specific area of the cell membrane adjacent to the bone surface called
the ruffled border. The ruffled border is the area of the bone surface which is undergoing
resorption. The attachment of osteoclasts to the bone surface requires cell membrane
1
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resorption. The attachment of osteoclasts to the bone surface requires cell membrane
bound proteins called mtregins. Osteoclasts resorb bone by producing proteolytic
enzymes and hydrogen ions under the ruffled boarder area (Blair et al., 1989).
Osteoclastic bone resoption may be stimulated by factors that enhance
proliferation of osteoclast progenitors, cause differentiation of osteoclast progenitors to
mature cells, or activate of mature mutinuleated cells to resorb bone. Therefore, by
inhibiting the agent that blocks proliferation of precursors or inhibiting resorption by the
mature multinucleated cells, one could inhibit bone resorption. Factors which have been
shown to stimulate osteoclastic bone resorption include parathyroid hormone (PTH)
(McSheehy and Chambers, 1986), 1,25-dihydroxyvitamin D (Roodman, et al., 1985),
interleukin-1 (IL-1) (Thomson et al., 1986), insulin-like growth factors (IGFs)
(Mochizuki et al., 1992), and tumor necrosis factor a (INFa) (Bertolini et al., 1986).
Factors which have been shown to inhibit osteoclastic bone resorption include calcitonin
(Chambers and Magnus, 1982), estrogen (hi& et al., 1992), neutral phosphate (Raisz and
Neimann, 1969), y-intreferon (Gowen et al.., 1986), and transforming growth factor
(TGF)-B (Chenu et al., 1988). In addition, bis phosphonates, synthetic non-hydrolyzable
pyrophosphate analogs, inhibit bone resorption and are used pharmacologically for this
purpose (Kleerekoper and Avioli, 1993).

2. Osteoblasts
Osteoblasts arise from cells in the condensing mesenchyme which become
committed as preosteoblasts and then differentiate into mature osteoblasts. During the
process of bone formation, some osteobla,sts become osteocytes encased in calcified
bone. There are several steps required for bone formation which are under the control of
the osteoblast : 1) synthesis and intracellular processing of the type I collagen;
2) secretion and extracelluar processing of the collagen; 3) the formation of microfibrils,
fibrils, and fibers from the collagen; 4) maturation of the collagen matrix with subsequent
nucleation and growth of the hydroxyapatite crystals; 5) synthesis and secretion of noncollagen bone matrix proteins; 6) osteoclast formation and bone resorption (Puzas, 1993).
Since osteoblasts play an important role in bone formation processes, factors that
regulate osteoblast functions, such as type I collagen synthesis or osteoblast proliferation,
could greatly affect bone formation. Factors which regulate ostoblast functions include:
PTH, 1,25 (OH)2D3 , TGF-B, bone morphogenic proteins (BMF's), insulin-like growth
factors (IGFs), glucocoricoids and sex steroids (Canalis, 1993; Puzas, 1993). The effects
of IGFs and sex steroids on osteoblasts will be described in the following sections.

3. Bone remodeling
Bone remodeling is a process in which a number of cellular fictions participate in
the coordinated resorption of old bone and formation of new bone. Two phases are
essential for bone remodeling (Eriksen, 1986). The first phase is bone resorption which
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involves the replication and differentiation of osteoclast progenitors, and migration of
differentiated osteoclasts to the bone surface, where they displace lining cells at the site
of resorption activation. The mature osteoclast forms a ruffled border area surrounded by
the clear or sealing zone, and then releases hydrogen ions to disslove the bone mineral
and lysosomal enzymes to degrade the underlying matrix. The second phase of the bone
remodeling cycle is the formation phase in which the osteoblasts replace resorbed bone.
Two major factors can greatly influence the bone formation phase: a) the presence of
resorbed bone surface which serves as a template for bone formation; b) the release of
local growth factors from cells or matrix which are required for osteoblast proliferation
(Parfitt, 1987). Imbalance in the bone remodeling process can lead to a pathological
state. The imbalance in the remodeling process in which an increase in bone resorption is
not coupled with an increase in bone formation can lead to osteopenia. An inadequate
coupling of bone formation to resorption can result in osteoporosis. In contrast, an
increase in bone formation without a balanced increase in bone resorption can cause
osteopetrosis which consists of excessive endosteal formation and calcification and leads
to spontaneous fractures and occlusion of the marrow space.

B. Osteoporosis and Sex Steroid Hormones
One of the most prevalent pathological states that results from imbalance in the
bone remodeling cycle is osteoporosis. Osteoporosis is a disorder in which rates of bone
resorption exceed bone formation, resulting in gradual but progressive bone loss and
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development of nontraumatic or atraumatic fractures (Kleerekoper and Avioli, 1993).
Osteoporotic fractures may affect any part of the skeleton except the skull. The incidence
is higher in whites than in blacks, and higher in women than men. Osteoporosis is
responsible for about 300,000 hip fractures and more than 1,000,000 total fractures each
year in United States. Current estimates indicate that each new case of osteoporotic hip
fracture will cost approximately $40,000 and that the annual expenditure for short-term
care following osteoporotic hip fractures has already exceeded $8 billion in the United
States (Kleerekoper and Avioli, 1993).
Sex steroid hormones are important in maintaining and preserving bone mass.
Albright et al. (1940) first noted that osteoporosis was seen in women with oophorectomy
before the usual age of menopause and first postulated that ovarian loss was in some way
causing the premature development of osteoporosis (Albright et al., 1940). Aitken et al.
(1973) showed that women whose ovaries were removed only 3 years previously had a
lower bone mass than women of the same age who had their uterus removed but whose
ovaries were left in place. Therefore, the loss, or lack of estrogen and other sex steroids
produced by the ovary is important in the development of osteoporosis in women (Riggs
et al., 1986). The principle effect of estrogen withdrawal is an increase in bone resorption
with no change in, or inadequately increase in, bone formation (Arlot et al., 1984). In
vitro experiments suggest that estrogen indirectly decreases bone resorption by
decreasing the synthesis of cytokines, such as interleuldn-6, which are present in the bone
microenvironment and play a role in the stimulation of bone resorption (Jilka et al.,

1992). Thus, estrogen will slow the rate of bone loss without affecting bone formation.
Clinically, the ability of estrogen to increase bone mass is limited, with the best result
being a 2-4 % annual increase for 2 years (Kleerekoper and Avioli, 1993).
Postmenopausal women do not only lack estrogen but also lack progesterone
(PG). In the normal human mentrual cycle, estrogen and PG secretion are linked. PG
secretion is high in the luteal phase of the ovalutory cycle, is low in the follicular phase,
and is a key hormone essential for the regulation of reproductive function in the body
(Clarke and Sutherland, 1990). Therefore, in the postmenopausal state, menstruation
ceases and the production of both estrogen and PG is also halted. Since sex steroid
hormones produced from the ovary are important in maintaining and preserving bone
mass, it is likely that PG also plays an important role in bone metabolism.
Several studies have shown that treatment of postmenopausal women with
progesterone alone reduces the markers of bone resorption (Abdalla et al., 1985; Eriksen,
1986; Linsay et al., 1978; Lobo et al., 1984; Selby et al., 1985). Treatment of
postmenopausal women with a combination of PG and estrogen increases serum alkaline
phosphatase and osteocalcin, markers of bone formation, to a greater extent than
treatment with estrogen alone (Christiansen et al., 1985). Using oophorectornized adult
beagle dogs as a model for bone metabolism, Kararnobolova et al. (1986) and Snow et al.
(1985) demonstrated that PG treatment promoted bone formation. in contrast, estrogen
decreased the number of osteoclasts but did not promote bone formation (Karamboloba et

at, 1987). Therefore, it appears that PG exerts its effects on bone formation whereas
estrogen exerts its effects on bone resorption to increase bone mass.
Although clinical and animal studies have established that PG prevents bone loss
by promoting bone formation, the detailed mechanisms underlying the protective effects
•of progestin are still unclear. In vitro studies, suggest that PG stimulates cell
•proliferation and differentiation in human osteoblast-like cells (Lau et al., 1994; Scheven
et al., 1992; Tremollieres et al., 1992; Verhaar et al., 1994). Human osteoblast-like
TE-85 cells were found to express progesterone receptors (PRs) and respond to PG in a
dose dependent manner with increased cellular alkaline phosphatase activity (Wei et al.,
1993). Since PRs are required for PG to mediate its effects, the presence of PRs in
human osteoblasts suggests that PG has direct effects on osteoblast functions. PG appears
to increase osteoblast proliferation by modulating the insulin-like growth factor (IGF)
system in the osteobla,st microenvironment (Lempert et al., 1992; Tremollieres et al.,
1992).

C. Molecular Mechanisms of Progesterone Action
•

PG is synthesized and secreted after ovulation from the collapsed follicle, the

corpus leuteum. The hormone then travels via the blood stream to target cells, enter these
cells by simple, or facilitated, diffusion, and then binds to PRs. Upon PG binding, the
receptor is activated, and can bind effectively to a specific DNA sequence called the

progesterone response element (PRE) to activate gene transcription. A simplified model
of PG action is shown in Figure 1.

1. Progesterone receptor and its isoforms
The PR belongs to the steroid hormone receptor superfamily which consists of a
large number of genes (Tsai and O'Malley, 1994). It includes receptors for the steroids,
estrogen (ER), progesterone (PR), glucocorticoid (GR), mineralocorticoid (MR), and
androgen (AR). in addition, it includes receptors for thyroid hormone (TR), vitamin D
(VDR), retinoic acid (RAR), and 9-cis retinoic acid (RXR). Amino acid sequence and
mutational analyses of these steroid hormone receptors indicate that they can be
subdivided into six domains : the A/I3 domain, DNA binding domain (C domain), hinge
region (D domain), ligand binding domain (E domain), and F domain. A schematic
representation of the domains is shown in Figure 2. The N-terminal A/B domain is
highly variable in length among members of the steroid receptor superfamily. This
domain contains a transactivation function (AF) which activates target gene expression
presumably by interacting with components of the core transcription machinery,
coactivators, or other transactivators (Hollenberg and Evan, 1988; Kumar et al., 1987).
The C domain contains two zinc fingers which are responsible for DNA recognition and
dimerization (Freeman, 1992). The D domain or hinge region may allow the receptor to
bend or alter conformation and often contains a nuclear localization domain (in GR and
PR) (Godowski et al., 1988).

Figure 1. Classical mechanism of PG action. A simplified model of the classical
mechanism of PG action. PG enters cells by simple or facilitated diffusion, and binds to
intracellular progesterone receptors (PRs). Upon binding PG, the receptors undergo an
activation or transformation step. The activated PR can then homodimerize, bind
effectively to a specific DNA element, progesterone response elements (PREs), and
activate gene transcription.
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Figure 2. Progesterone receptor isoforms. Schematic representation of PR isoforms.
The modular structure of PR is depicted. A and B represent PR isoform A and B,
respectively. Numbers above the receptor represent the amino acid positions of each
domain.
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The E-region is relatively large compared to other domains. It contains regions important
for heat-shock protein association, dimerization, nuclear localization, transactivation, and
ligand-binding (Tsai and O'Malley, 1994),In the PR, this region also contains domains
essential forintermolecular silencing in which the silencing activity is relieved upon
binding to PG (Picard and Yamamoto, 1987). The major dimerization domain of steoid
hormone receptors is localized in the C-terminal half of the ligand binding domain
(Fawell et al., 1990). This region contains leucine-rich sequences that may form coil-coil
interactions as the receptor dimerizes. No specific function has been assigned to the
F-domain.
Two forms of PR, amino terminal truncated PR-A and full length PR-B, have
been identified in most species with the exception being the rabbit where PR exists as a
single unique B-subtype (Loosfelt et al., 1986). In human cells, the PR is expressed
primarily as two forms, full length PR-B (Mr 114 IcDa) and N-terminal truncated PR-A
(Mr 94 Id)a) (Kastner et al., 1990). The PR-A isoform lacks the first 164 amino acid at
the N-terminus (Figure 2). The two receptors are synthesized from a single gene by
alternate initiation of translation from a single PR mRNA (Coneely et al., 1987), or by
alternate transcription from two promoters (Kastner, et al., 1990). Since the two
receptors in human cells can be individually regulated and transcribed from two distinct
promoters, it is likely that the expression levels of PR-A and PR-B can differ with respect
to each other in certain target tissues. In support of this hypothesis, it has been shown
that the relative expression of PR-A and PR-B in human endometrium changes during the
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human menstrual cycle, suggesting that the two different PR promoters can be regulated
independently in this organ (Feil et al., 1988). In addition, the relative levels of PR-A
and PR-Bare different in biopsies of uterine leiomyomas compared with their expression
in adjacent normal endometrium (Brandon et al., 1993).
The precise functions of PRA and PR-B have not yet been well defined. The two
isoforms have different functional properties. The transcriptional activities of PR-A and
PR-B are dependent upon cell and promoter context (Myer et al., 1992; Vegato et al.,
1993). PR-B activates transcription, in most cases, whereas PR-A acts as a transdominant repressor of PR-B and other receptors such as GR, MR, and AR (Tung et al.,
1993; Vegato, et al., 1993; Wen et al., 1994). The repressor function of PR-A is cell and
target gene specific. In a few cases, only PR-A, but not PR-B, activates gene
transcription. When an ovalbumin promoter-CAT constructs is cotransfected into Hela
cells with a chicken PR-A (cPR-A) or chicken PR-B (cPR-B) expression vector, only
cPR-A was able to activate gene transcription (Tom et al., 1988). This is the only
example of PRA specific transactivation of gene transcription. Thus, PR-A has the
potential for two functions, activation and repression, depending on the cell and
promoter context.
In addition to PR-A and PR-B, two additional transcripts that lack both the A and
B translation start site have been mapped. These transcripts contain downstream
translation sites that if utilized would generate proteins with a partial DNA-binding
domain and complete hormone binding domain (Wei et al., 1990). A third PR isoform
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(PR-C) exists in breast cancer cell lines T47D, MCF-7 , and normal human
enclometrium (Wei and Miner, 1994). PR-C has a molecular weight of approximately
60 IcDa and binds specifically to PG and synthetic progestin, R5020, with the same
affinity as PR-A and PR-B (Wei and Miner, 1994). The function and regulation of PR-C
is still unknown.

2. Activation of the progesterone receptor
PR is activated primarily through binding to PG. PG then transactivates PR to
bind to PRE. A series of events takes place once PR binds PG. The physiologically
inactive form of the receptor exists as an oligomeric complex with proteins such as heat
shock protein (hsp) and immunophilin (Bauleu, 1987; Smith and Toft, 1993). Initially,
PR is associated with a multiprotein complex consisting of hsp90, hsp70, and a small
protein called p60. The initial multiprotein complex is rapidly displaced by another
protein complex consisting of hsp90, p23, and any of the large imrnunophilins (FKBP52,
•FKB54, or CyP40) (Smith, 1993; Smith and loft, 1993). This mature PR complex is
thought to be stable unless disrupted by hormone binding. Upon binding to PR, PG
•induces a conformational change which displaces these multiprotein complexes and
allows the uncomplexed receptor to interact with DNA (Tsai and O'Malley, 1994). The
hsp containing complexes interfere with, or block, DNA binding (Picard et al., 1988).
However, the removal of hsp complexes alone is not enough to activate PR. Ligand
binding is essential for activating PR to bind to DNA (Bagchi et al., 1991). The role of
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ligand in DNA binding is to induce a conformational change in the ligand binding
domain, which exposes the major dimerization domain in this region, allowing receptor
dimerization. The dimeric receptor can then bind to a PRE with high affinity (Allan et
al., 1992; Tsai et al., 1988)
A major additional process that enhances PG-dependent activation of receptors is
phosphorylation. Phosphopeptide-mapping indicates the presence of multiple
phosphorylation sites in human PR, predominantly on serine (Sheridan et al., 1989). PR
phosphorylation increases after hormone treatment (Sullivan et al., 1988). A significant
level of phosphorylation occurs only after the activated receptors bind to DNA (Bachi et
al., 1992). Beck et al. (1992) proposed that phosphorylation of human PR involves at
least three rounds of phosphorylation: constitutive phosphorylation in the absence of
hormone, rapid hormone-dependent phosphorylation, and a much slower phosphorylation
after the receptor binds to DNA. Rapid hormone-dependent phosphorylation could be
involved in the enhancement of PR-DNA binding or in promoting receptor dissociation
from heat shock proteins. The third round of phosphorylation which takes place after PR
binding to DNA suggests that this DNA-dependent phosphorylation might be important
in regulation of transcriptional activity (Beck, et al., 1992).
Several activators of cell signal transduction pathways can potentiate
PG-dependent PR-mediated gene transcription. Effects have been observed with
activators of protein kinase A, protein kinase C, and with okadaic acid, a phosphatase
inhibitor (Beck, et al., 1992; Beck et al., 1993). These agents enhance the transcriptional
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activity of PR but do not effect PR protein synthesis or DNA binding. Unlike ER and
chicken PR which can be activated without binding to ligands (Power et al., 1991),
ligand-independent activation of human PR has not been successfully demonstrated
(Edwards et al., 1995).

3. Glucocorticoid/Progesterone Response Elements (GRE/PRE)
The term hormone response element

) is used for DNA elements which

recognize and bind nuclear hormone receptors (Yamamoto, 1985). The first
characterized HRE was the glucocorticoid response element (GRE) in the mouse
mammary tumor virus (MMTV) promoter. The glucocorticoid-stimulated expression of
genes encoding the virus is mediated by short sequences localized upstream of its
promoter (Yamamoto, 1985). These DNA sequences confer hormone control to
heterologous genes at a distance and in an orientation independent manner (Chandler et
al., 1983). This region correlates very well to the long terminal repeat (LTR) of the
MMTV promoter and contains as high affinity binding sites for partially purified rat liver
OR (Payvar et al., 1983).
After characterization of the MMTV promoter, GRE's of several glucocorticoid
inducible genes were described, including human metallothionein HA (Karin et al.,
1983), chicken lysozyme (von der Ahe et al., 1988), moloney murine sarcoma virus
(Mikisicek et al., 1986), rat tyrosine aminotransferase (Jantzen et al., 1987), and rat
tryptophan oxygenase (Danesch et al., 1983) were reported as glucocorticoid inducible.
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Sequence comparison of promoters which bind the glucocorticoid receptor identified a
15 base-GRE consensus sequence of 5'-GGTACANNNTGTTCT-3', where N is any
base (Beato et al., 1989). The 3'-half of the consensus sequence contains the motive
TGTTCT which is found in almost 90% of the GREs, suggesting that this 3'-half of the
GRE plays an important role in interaction with the receptor. The 5'-half of GRE is less
conserved among GREs (Beat°, et al., 1989).
GR, PR, AR, and MR are related and belong in the same family (Tsai and
O'Malley, 1994). These receptors can bind to the same or similar HREs. This may be
due to the strong conservation of the DNA binding domain within members of this
receptor family. For example, human GR differs from human PR in only 6 of 70 amino
acids in the DNA binding domain (Hollenberg et al., 1985; Misrahi et al., 1987). In
addition, the target site specificity of the these receptors, especially GR and PR, is very
similar (von der Ahe, et al., 1988). in the MMTV promoter, the LTR region can also
bind and be activated by PR, AR, and MR, in addition to GR (Arriza et al., 1987; Cato et
al., 1987). In the human metallothionein IIA promoter, PR binds to the GRE (Slater et
al., 1988).
Although GR and PR can bind to the same, or similar, target sites, these receptors
can recognize or use target sites differently (Gowland and Euetti, 1989; Nordeen et al.,
1989). Glucocorticoids induce promoter activity to a severalfold greater extent than PG
in the MMTV promoter expressed in a human breast carcinoma cell line, T47D (Nordeen,
et al, 1989). Mutations of the MMTV promoter differentially affect responses to the two
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hormones (Gowland and Euetti, 1989). In addition, there are slight differences in the
DNase I footprints generated by the binding of the two receptors to DNA containing the
MMTV GRE/PRE (Chalepakis et al., 1988).
Classically, the consensus GRE/PRE is composed of two hexameric half-sites
arranged as a palindrome with a 3 bp spacer. Analyses of a series of point substitution
and insertion mutations of the distal receptor-binding site of the MMTV promoter have
defined optimal recognition sequences for PR and GR (Lieberman et al., 1993; Nordeen
et al., 1990). The optimal receptor binding site for GR (GRE) is GGNACAnnnTGINCC
(Nordeen, et al., 1990) and for PR (PRE) i (A/G)GNACAnnnTGINC(C/T) (Lieberman,
et al., 1993). In addition to binding the classical palindromic GRE/PRE, both PR and GR
can bind weakly to a hexanucleotide motif, half-site 5'-TGTTCA-3'(Scheidereit et al.,
1983). Clusters of this hexanucleotide motif which occur in MMTV, uteroglobin, and
other promoters can bind GR/PR and effectively activate transcription through synergistic
interaction between the sequences (Bailly et al., 1986; Beato, et al., 1989)
In addition to interacting with GRE/PRE, GR/PR have been shown to interact
with other nuclear proteins such as CACCC-box binding proteins (Muller et al., 1991;
Schule et al., 1988), c-fos (Jonat et al., 1990), and c-jun (Schule et al., 1990; Yang-Yen et
al., 1990) thereby modulating receptor activity. Schule et al. (1988) demonstrated that
the cooperatively between GR and CACCC box binding proteins synergized in
glucocorticoid induction of gene transcription. In contrast, interaction between GR/PR
and c-jun or c-fos resulted in inhibition of GR/PR-induced gene transcription (Schule et
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al., 1990; Shemshedini et al., 1991). Overexpression of c-jun prevented the
glucocorticoid-induced activation of genes carrying a functional GRE/PRE (Schule et al.,
1990). Shemshedini et al. (1991) showed that transcriptional activation by human PR in
the human breast cancer cell line, T47D, could be inhibited by increasing intracellular cfos. Although the precise mechanism of how c-fos and c-jun inhibit hPR/hGR
transactivation of gene transcription is still unclear, there is some evidence that c-fos or
c-jun might inhibit hPR/hGR activity by competing for factors which are required for
activation of the receptors (Shemshedini et al., 1991). Alternatively, Jonat et al. (1990)
demonstrated that GR coprecipitated with the AP-1 complex (Fos-Jun) suggesting direct
binding of the GR to the AP-1 complex and inhibition of GR-mediated transactivation
activity.

D. Insulin-like Growth Factor (IGF) System and Bone Metabolism
1. Components of the skeletal IGF system
The IGF system in bone consists of IGF-I and IGF-II, IGF receptors, IGF binding
proteins (IGF13Ps) and IGFBP protease& The IGFs are important autocrine and paracrine
regulators of proliferation and differentiation in many cell types including osteoblasts
(Jones and Clemrnons, 1995; Mohan and Baylink, 1991a; Rosen et al., 1994). IGFs are
the most abundant growth factors produced by bone cells and stored in bone (Mohan and
Baylink, 1991c). IGFs stimulate two essential components of bone formation, bone cell
proliferation (Baylink et al., 1993), and type I procollagen synthesis (Hock et al., 1988),
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in vitro. Endogeneous IGFs are potent mitogens for human osteoblasts and contribute to
about 40-50% of total basal osteoblast proliferation in serum-free cultures (Mohan et al.,
1989). IGFs increase bone formation in vivo both in rat and human (Johansson et al.,
1992; Zapf and Foresch, 1986). In addition, IGF-I and IGF-II interact synergistically
with 1,25(OH)2D3 to increase production of osteocalcin, a marker of bone formation, in
rat and human osteoblasts (Fournier et al., 1993). Since there are several components of
the IGF system in the bone microenvironment, IGF activities can be regulated by
modulating components of the IGF system such as the IGFs, IGF receptors, or IGF
binding proteins. Very little is known about the significance and regulation of IGFBP
proteases.

2. IGF-I and IGF-II
Historically, IGFs were first discovered in 1957 by Salmon and Daughaday
(1957) as a sulfation factor, based on their ability to stimulate cartilage sulfation in vitro
in the absence of exogenous GH. IGFs were also discovered independently for other
biological activities. Foresch et al. (1963) identified the nonsuppressible insulin-like
activity of a serum factor that exerted insulin-like action on muscle and adipose tissue
even in the presence of anti-insulin antibodies. Dulak and Temin (1973) partially purified
polypeptide from serum-free conditioned medium of BRL-3A rat hepatoma cells which
stimulated embryo fibroblast proliferation. All three biological factors were unified and
termed somatomedin (Daughaday et al., 1972). Later, Rinderknecht and Humbel (1978a;
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1987b) purified two distinct somatomedins and called them insulin-like growth factors I
and II (IGF-I and IGF-II) based on amino acid sequence homology to insulin.
IGF-I and IGF-II are single chain polypeptides with three intrachain disulfide
bridges and molecular weights of 7.6 and 7.5 ic,Da respectively. IGF-I and IGF-II share
60% amino acid sequence homology (Rinderknecht and Humble, 1978; Rinderknecht and
Humble, 1978). The human IGF-I gene is located on chromosome 12 and is
approximately 90 kb in length while the human IGF-H gene is approximately 30 kb in
length and located on chromosome 11 (Sussenbach, 1989; Tricoli et al., 1984). Two
IGF-I mRNA transcripts (IGF-1A and IGF-IB) are expressed during pre- and post-natal
development in humans (Han et al., 1988). At least three different size IGF-II mRNA
transcripts (4.9, 5.3, and 6.0 kb) resulting from alternative promoter usage and alternate
mRNA slicing are expressed in many cell types (Daughaday and Rotwein, 1989; Schneid
et al., 1993).
IGFs are important growth factors for pre- and postnatal bone development as
demonstrated in homologous nul mutation (knock out) transgenic mice. in IGF-I knockout transgenic mice, surviving mutants have abnormal bone development and are smaller
in size (Baker et al., 1993). In IGF-II knock out transgenic mice, new horns homozygous
for the disrupted IGF-II gene demonstrate severe growth retardation and die shortly after
birth (Liu et al., 1993).
in humans, the highest expression of IGF-I is found in liver (Han, et al., 1988).
Liver is also the major source of serum IGF-I, but skeleton IGFs also enter the total
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circulating IGF pool. In rats and mice during fetal development, the level of IGF-II in
serum is higher than IGF-I. However, during post-natal life the IGF-I levels are higher
than IGF-II levels (Daughaday et al., 1982). In constrast to rats and mice, human and
guinea pig IGF-II levels in adult serum remain higher than IGF-I levels (Daughaday et
al., 1986; Enberg et al., 1984). IGF-I is produced at a much lower level than IGF-II by
human osteoblasts in vitro (Mohan and Baylink, 1991c). IGF-I production in many
human osteoblastic cell preparations is almost =detectable (Mohan et al., 1990). Unlike
human bone cells, cultured rat and mouse bone cells produce more IGF-I than IGF-II
(Mohan and Baylink, 1991c), suggesting that the regulation of the IGF system in rat and
mouse may be different from human.
IGFs in skeletal tissue come from three sites: the circulation, the osteoblasts
(Mohan and Baylink, 1991), and the bone marrow stromal cells (Zhang et al., 1991). The
osteoclasts do not produce IGFs and IGFBPs. However, IGFs may promote osteoclast
differentiation (Mochizuki, et al., 1992). During the bone resorption process, IGFs are
released from bone matrix and act on osteoblasts to stimulate osteoblast proliferation.
Expression of IGFs is regulated by both systemic and local agents. IGF-I, but not IGF-II,
expression is directly regulated by GH (Daughaday et al., 1987). In fetal rat bone cell
cultures, PTH increases IGF-I expression at both the protein and mRNA levels
(McCarthy et al., 1989). The effect of PTH on IGF-I expression can be duplicated using
cAMP analogues (Canalis et al., 1989). In contrast to rat bone cells, PTH, has no effect
on the synthesis of either IGF-I or IGF-II in human bone cells (Finkelman et al., 1992).
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Pharmacologic doses of cortisol dramatically suppresses production of IGF-I and IGF-II
(McCarthy et al., 1989) in cultures of rat osteoblast-enriched cells. Physiological
concentrations of 1,25(OH)2D3 (10-10-10

inhibit both basal and PTH stimulated

IGF-I but not IGF-II production in mouse calvaria cells (Linichart and Keifer, 1991). In
addition to those systemic factors, several local factors also regulate skeletal IGF
synthesis. TGF-13 stimulates the release of both IGF-I and IGF-II in neonatal mouse
calvaria (Linichart and Keifer, 1991), and IGF-I from mouse osteoblasts (Tremolliers et
al., 1991). Fibroblast growth factor (FGF) suppresses IGF-I and IGF-II synthesis in
osteoblast-enriched cells from fetal rat calvaria (Canalis et al., 1993). Prostaglandin E2
(PGE2) stimulates IGF-I production in mouse calvaria cells (Linichart and MacCharles,
1992) whereas platelet derived growth factor (FDGF) suppresses IGF-I production in rat
calvaria cells (Canalis, et al., 1993). BMP-7 stimuates IGF-Ii production in human bone
cells (Knutsen et al., 1995)
IGF production is regulated by sex steroids. Estrogen induces IGF mRNA
expression in reproductive tissues (Murphy et al., 1989). In UMR-106 rat osteosarcoma
cells, estradiol increases the release of IGF-I and TGF-13 (Gray et al., 1987). Furthermore,
the bone forming effect of estradiol is blocked by anti-IGF-I antibodies (Ernst et al.,
1989). In addition to estrogen, progesterone (PG) stimulates human bone cell
proliferation and increases IGF-II mRNA levels and protein production (Tremollieres et
al., 1992).
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3. IGF receptors
Two types of IGF receptors have been identified in bone cells: type I receptors
and type II IGF/manose 6-phosphate receptors (Mohan and Baylink, 1991c). Most of the
cellular effects of IGFs are mediated by binding of the peptides to the IGF receptors and
transmitting the signals into the nucleus. The type I IGF receptor is a heterodimeric
protein (a2B2) in which the a- (130 kDa) and B-subunits (90 kDa) are linked by disulfide
bonds to form an ccB-half-receptor which are subsequently linked to another aB-halfreceptor to form the mature a2B2-holoreceptor (Ullrich et al., 1986). Ligand binding
specificity is conferred by the cysteine-rich region in the a-subunit extracellular domain
(Ulrich, et al., 1986). The human type I IGF receptor gene is located on chromosome 15
(Ullrich, et al., 1986). The signal transduction of the receptor is conferred by a tyrosine
kinase activity domain that resides in the cytoplasmic B-subunit (Czech, 1989). The
IGF-I receptor has a high degree of sequence homology (-50-60% sequence identity ) to
the insulin receptor with the highest homology (84%) in the tyrosine kinase domain
(Czech, 1989). The type I receptor has the highest affinity for IGF-I with approximately
100 to 1000 fold lower affinity for insulin and 2 to 15 fold lower affinity for IGF-II
(Steele et al., 1988).
The signal transduction of type I IGF receptors is very similar to the insulin
receptor. The binding of IGF-I causes tyrosine phosphorylation of an 185 kDa, insulin
receptor substrate-1 (IRS-1)(Izurni et al., 1987). The phosphorylated IRS-1 can bind to at
least two src homology 2 (S112)-containing proteins: 1) the p85 regulatory subunits of
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phophatidylinosito1-3 kinase (PI-3 kinase) (Yamamoto et al., 1992); and 2) growth factor
receptor-bound protein 2 (Grb2) (Skolmic et al.., 1993). The binding of IRS-1 to the p85
of PI-3 kinase results in the activation P1-3 kinase and phosphorylation of phosphotidyl
inositol 4,5-bisphosphate (PIP2). The subsequent formation of phophatidylinosito1-3,4,5
triphosphate serves as a signal for cell growth. The activated Grb2 can further complex
with the guanine nucleotide exchange factor, Son of sevenless (Sos) (Skolnik et al.,
1993). Formation of this complex is necessary for the activation of Ras (Baltensperger et
al., 1993). Activated Ras then activates Raf causing the activation of mitogen activating
protein kinases (MAP kinases) which ultimately transmit signals to the nucleus (Blenis,
1993).
The type II IGF receptor is a monomeric receptor that binds to manose-6phosphate (Man-6-P) residues on lysosomal enzymes (Nielsen, 1992). Type II IGF-II/
Man-6-P receptors bind IGF-II with high affinity and bind IGF-I with a 500 fold lower
affinity. This receptor does not bind insulin (Nielsen, 1992). The binding site for IGF-II
is distinct from the binding site for Man-6-P and Man-6-P containing glycoproteins
(Braulke et al., 1988). In mice, IGF-II/Man-6-P receptor Igf2r) and IGF-II (Igf-2) genes
are subject to parental imprinting such that only the maternal allele of Igf2r and the
paternal allele of Igf2 are preferentially expressed (Barlow et al., 1991; DeChiara et al.,
1991). In humans, however, the Igf2 gene is imprinted while the Igf2r gene is not
(Ohlsson et al., 1993).
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The signal transduction pathway of the type 11 IGF-II/ Man-6-P receptor is not
well understood. IGF-II iiiediates an increase of Ca++ influx which, in turn, stimulates
DNA synthesis in BALB/c 3T3 cells (Nishimato et al., 1987). The increase of Ca++
influx and DNA synthesis can partially be explained by the following pieces of data:
1) the receptors couple to GTP-binding proteins; and 2) binding of IGF-II to the receptor
stimulates binding of GTP7S to G12 and increases GTPase activity which results in an
increase in Ca++ influx (Muruyama et al., 1990), and ultimately transmits the signal into
the nucleus.
The physiological role of the IGF-II/Man-6-P receptor is unclear. However, the
receptor may function in degradative pathways to remove IGF-II from the extracellular
environment (DeChiara et al., 1990). It remains =certain whether the biological action
of IGF-II is mediated via the type II IGF-II/Man-6-P receptor. Several lines of evidence
suggest that the biological action of IGF-II may be mediated by the IGF-1 receptor.
Treating H-35 hepatoma cells (Mottola and Czech, 1984), normal hepatocytes(Hartmann
et al., 1992), L6 myoblasts (Kiess et al., 1987), and ovarian granulosa cells (Adashi et al.,
1990) with antibodies directed against the IGF-II/Man-6-P receptor has no effect on
biological responses to IGF-II. In addition, a blocking monoclonal antibody (aIR-3)
against the IGF-1 receptor blocked both IGF-I and IGF-II stimulated [31-I]thyrnidine
incorporation into DNA in human fibroblast cultures (Flier et al., 1986; Van Wyk et al.,
1985). However, in bone cells, which contain type II IGF-II receptors, blocking
antibodies against the type II IGF-II/Man-6-P receptor inhibited IGF-H induced
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osteoblast proliferation while the IGF-I blocking antibody, aIR-3, was ineffective in
blocking IGF-II stimulated proliferation in mouse osteoblasts (Mohan and Baylink,
1991c), suggesting that the type II IGF-II/ Man-6-P receptor is important for bone cell
proliferation. Consistent with this conclusion, treatment of human osteoblasts with PG
increases the type II IGF-II/Man-6-P receptor mRNA levels and increases bone cell
proliferation (Lempert et al., 1992).

4. IGFBPs
In addition to the IGFs and their receptors, IGFBPs present in the bone cell
microenvironment also play an important role in regulating IGF activities. In the
circulation and throughout the extracellular space, the IGFs bind with high affinity to
IGFBPs. Six IGFBPs of different molecular weights (IGFBP-1, -2, -3, -4, -5, and -6)
have been identified. (Shimasaki and Ling, 1991). The IGFBPs share structural
homology with each other and specifically bind the IGFs. All human IGFBPs, except
IGFBP-6, contain 18 homologous cysteines; twelve of which are located at the
N-terminal in the first one-third of the total amino acid sequence (Shimasaki and Ling,
1991). The physiological function of IGFBPs is still unclear. The IGFBPs 1) act as
storage and transport proteins for the IGFs, 2) prolong the half-lives of IGFs, 3) provide
tissue and cell type-specific localization, and 4) modulate the biological actions of the
IGFs (Jones and Clemnions, 1995).
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Five different molecular weight IGFBPs (25, 29, 34, 38.5, and 41.5 kDa forms)
have been identified in human bone cell (HBC) cultures (Mohan and Baylink, 1991b).
Most HBC (except MG63 osteosarcoma cell line) cultures produce IGFBP-2 through -6
(Mohan and Baylink, 1991b). No immunoreactive IGFBP-1 is detected in HBC cultures
(Mohan and Baylink, 1991b). Under serum free culture conditions, the 25 kDa and 38.541.5 kDa IGFBPs are the two most abundant IGFBPs produced by bone cells (Mohan and
Baylink, 1991b). The 25 kDa protein is IGFBP-4; the 38.5-41.5 kDa protein is IGFBP-3;
and the .34 1(13a protein is IGFBP-6. A 24 kDa protein detected in some HBC cultures is a
proteolytic fragment of IGFBP-5 (Bautista et al., 1991; Mohan and Baylink, 1991b). The
amount and type of IGFBPs produced by normal HBC derived from different sites and by
different osteosarcoma cell lines are different (Hassager et al., 1992; Mohan and Baylink,
1991b), suggesting that the pattern of IGFBP expression is cell type and differentiation
stage specific. In addition, expression of each of the IGFBPs produced by HBCs is
modulated differently by various effectors (Hassager, et al., 1992). IGFBPs in HBCs are
regulated by various systemic and local factors. The regulation of each IGFBP,
especially in osteoblastic cells, is described below.

a. IGFBP-1
Human IGFBP-1 is a 25 kDa protein produced by human hepatoma cells, Hep G2
(Rechler and Nissley, 1990), and rat osteosarcoma cells, UMR-106 (Koutsilieris and
Polychronakos, 1992). In MG63 human osteosarcoma cells, Campell and Novak (1991)

found that IGFBP4 inhibited IGF-I induced cell proliferation. However, IGFBP-1 has
no effect on IGF-I induced cell proliferation in chick calvaria cells(Mohan et al., 1989).
Since IGFBP-1 is produced by a limited number of HBCs and human osteosarcoma cell
lines, it is not likely that IGFBP-1 plays an important role in modulating the IGF system
in the bone microenvironment.

b. IGFBP-2
Human IGFBP-2 is a 31.4 IcDa protein (Lamson et al., 1989) which binds to
IGF-II with 10 fold higher affinity than it binds to IGF-I (Brinkert et al., 1989). IGFBP-2
is expressed in various cell types including adult human brain and liver cells (Brinkert, et
al., 1989), adult rat brain, testes, and ovary (Margot et al., 1989), and rat osteoblasts
(Schmid et al., 1989; Schmid et al., 1992). However, in human bone cells, IGFBP-2 is
expressed only in the osteosarcoma, TE85, and not in other human osteoblast-like cells
(Bautista, et al., 1991; Mohan and Baylink, 1991). At high IGFBP-2: IGF-I ratio (10:1),
IGFBP-2 inhibits IGF-1 induced rat calvaria cell proliferation (Fayen et al., 1991). In rat
osteoblasts, IGF13P-2 expression is increased by 1,25(0f1)2D , triiodothyronine (T3), and
PTH, but does not respond to GH or retinoic acid (Chen et al., 1991; Schmid, et A,
1992).
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• c. IGFBP-3
Human IGFBP-3, the main carrier of IGFs in serum, is a 46-53 kDa protein that
contains three potential N-linked glycosylation sites (Baxter and Martin, 1989). In
serum, most of the IGF circulates as a 150 kDa complex consisting of IGF-I or IGF-II,
IGFBP-3 and an 85 kDa acid-labile subunit (ALS) (Baxter and Martin, 1989). ALS
contains several leucine rich domains which interact with IGFBP-3 (Leong et al., 1992).
The binding of IGFs to IGFBP-3 in the presence of ALS stabilizes IGF binding and
prolongs the half-lives of IGFs from less than 10 min for free IGFs to 12-15 h for IGFs in
150 kDa ternary complexes (Guler et al., 1989; Hodgkinson et al., 1989). IGFBP-3 is
produced in many peripherral tissues, but not liver, while ALS production is observed
mostly in liver (Rechler, 1993). IGFBP-3 may enhance or inhibit the actions of IGFs
depending upon cell types and culture conditions. When IGFBP-3 is added at the same
time with IGF-I, IGFBP-3 inhibits basal, and IGF induced, bone cell proliferation.
However, if the cells are preincubated with IGFBP-3 before adding IGF-I, IGFBP-3
enhances IGF actions at low concentration but inhibits IGF actions at high concentration
(Mohan, 1993).
• IGFBP-3 expression is regulated by various local and systemic regulators. IGF-I
and GI-I stimulate IGFBP-3 production in vivo (Schmid et al., 1989; Zapf et al., 1989).
•IGF-I , TGF-B, Gil, 1,25(011)2D3, and bone morphogenic protein (BNIP)-7 stimulate
while dexamethasone inhibits IGFBP-3 production in human osteoblast-like cells
(Knutsen et al., 1995; Nakao et al., 1994; Scharla et al., 1993; Schmid et al., 1989).

32
•d. IGFBP-4
Human IGFBP-4 is a 24 kDa binding protein with N-linked glycosylation sites
which inhibits IGF actions in all cell types and cult= conditions tested (La Tour et al.,
1990; Mohan, et al., 1989). IGFBP-4 accounts for almost 90% of all IGFBPs secreted
from mouse osteoblasts (Scharla et al., 1991). Addition of exogenous IGFBP-4 to mouse
osteoblasts, MC313-E1, inhibited basal and IGF-I induced cell proliferation (Amarnani et
al., 1993). Consistent with these findings, Malpe et al. (1992) reported that addition of
IGFBP74 antisense oligodeoxyribonucleotide to inhibit IGFBP-4 expression stimulated
bone cell proliferation In addition to inhibiting bone cell proliferation, IGFBP-4 may play
a role in bone cell differentiation. The addition of the potent bone cell differentiation
agent, 1,25 (OH)2D3, increases IGFBP-4 production and decreases bone cell proliferation
(Scharla et al., 1993). These results suggest that IGFBP-4 inhibits the proliferative
affects of IGFs and allows the cells to start the differentiation processes.
IGFBP-4 expression is increased by PTH, cyclic AMP analogues, and 1,25
(OH)2D3 (La Tour, et al., 1990; Scharla et al., 1993) and is inhibited by IGF-I, IGF-II,
progesterone, and BMP-7 (Knutsen et al., 1995; Lempert et al., 1992; Scharla et al.,
1991). Circulating levels of IGFBP-4 may reflect changes in the IGF system in the bone
cell microenvironment. Elderly women with hip fractures have high serum levels of PTH
and IGFBP-4 (Rosen et al., 1992). In addition, psoriasis patients who have chronic
exposure to 1,25 (OH)2D3 have •elevated levels of serum IGFBP-4 (Scharla et al., 1993),
consistent with the in vitro findings that 1,25 (OH)2D3 stimulates IGFBP-4.
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e. IGFBP-5
Human IGFBP-5 has the molecular weight of 29 kDa and has been purified from
human bone (Bautista, et al., 1991), adult rat serum (Shimasaki et al., 1991),
cerebrospinal fluid (Binoux et al., 1991), and gliobalstoma T98G cells (Camacho et al.,
1992). IGFBP-5 binds with higher affinity to IGF-II than IGF-I (Martin et al., 1990).
Human IGFBP-5 is composed of 252 amino acids, contains 18 conserved cysteine
residues with 0-glycosylation sites (Bautista, et al., 1991; Shimasaki et al., 1991).
IGFBP-5 cDNA clones were isolated from human placenta (Shimasaki et al., 1991), U2
osteosarcoma (Kiefer et al., 1991), and rat ovary cDNA (Shimasaki et al., 1991). Of the
six IGFBP cDNAs, IGFBP-5 is the most conserved with 97% identity among the human,
rat, and mouse amino acid sequences (James et al., 1993). The human and rat IGFBP-5
genes encode multiple mRNA transcripts between 5 and 6 kb (Shimasaki et al., 1991).
Normal human osteoblasts express a single 6.0 kb inRINA (Chevalley et al., 1996).
IGFBP-5 is expressed in most tissues including testis, uterus, intestine, adrenal, stomach,
spleen, heart, lung, muscle, brain, and liver (Shimasaki et al., 1991). The human
IGFBP-5 (hIGFBP-5) gene has been cloned and localized to the 2q33-34 region on
chromosome 2 tightly linked with, and in the opposite transcriptional orientation as, the
human IGFBP-2 gene (Allander et al., 1994). The gene is divided into four exons which
span —33 kilobase (kb) of DNA with the first intron spanning approximately 25 kb
(Allander, et al., 1994).
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hIGFBP-5 is the major IGFBP stored in bone and has consistently been shown to
enhance the mitogemc action of IGFs. Coincubation of mouse MC3T3-E1 osteoblasts
with equimolar concentration of IGF-II and IGFBP-5 results in potentiation of IGF-II
action (Bautista, et al., 1991). Andress et al. reported that a mixture of IGFBP-5 and
IGFBP-6 recovered from an IGF affinity column stimulated IGF-I potentiated DNA
synthesis in osteoblasts (Andress and Birnbaum, 1991). Recombinant human IGFBP-5
purified from yeast inhibited DNA synthesis in Sa0S2/B10 human osteosarcoma cells
(Keifer et al., 1992). However, subsequent studies from the same laboratory showed that
recombinant IGFBP-5 stimulated DNA synthesis in osteoblasts (Andress et al., 1993). In
•addition to enhancing the mitogenic action of IGFs, IGFBP-5 binds with high affinity to
hydroxyapatite (Bautista et al., 1991) and to various matrix proteins such as type III and
IV collagen, laminin, and fibronectin (Jones et al., 1993). These unique properties of
IGFBP-5 suggest that IGFBP-5 plays an important role in fixing IGFs to the extracellular
matrix including mineralized bone. Consistent with this observation, recent studies have
shown that the skeletal content of IGFBP-5 and serum IGFBP-5 levels decreased by
about 32% between the age of 20 and 60 (Mohan et al.., 1995; Nicolas et al., 1995),
suggesting that these age-related losses of IGFBP-5 may, in part, contribute to age related
bone loss.
The storage of the purified 29 IcDa IGFBP-5 protein at 4 C overnight leads to the
disappearance of the 29 IcDa IGFBP-5 band on polyacrylamide gels and appearance of a
major band at 24 kDa with lower molecular weight minor bands (Bautista et al., 1991),
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suggesting that the 29 kDa IGFBP-5 is degraded by proteases present in the IGFBP-5
preparation. Proteases with molecular weights of 52-72 and 97 Ma which degraded
IGFBP-5 in MC3T3-E1 mouse osteoblast cultures have been characterized (Thrailkill et
al., 1995). The 52 and 69-72 kDa proteases are cation dependent, inhibited by a tissue
inhibitor of metalloproteinase 1, and immtmoprecipitated with antisera to human matrix
metalloproteinase (MMP)-1 and MMP-2, respectively, suggesting that the murine MMP
homolog degrades IGFBP-5 (Thrailkill et al., 1995). The identity of the 97 kDa proteases
is still unknown. The production of IGFBP-5 proteases in human osteoblast cultures has
recently been demonstrated. IGFBP-4 and IGFBP-5 protease activities are detected in the
conditioned medium of U2 human osteosarcoma cells and untransfromed HBCs derived
from skull (Kansaki et al., 1994). The proteases have molecular weights of 160 and
67 kDa and are inhibited by aprotinin, zinc chloride, and EDTA (Kansalci et al, 1994).
Human fibroblasts also secrete IGFBP-5 proteases (Nam et al., 1994). This protease is
calcium-dependent serine protease with properties similar to kallikreins, a family of
serine proteases that degrade epidermal and nerve growth factors. The protease is
specific for IGFBP-5 and its proteolytic activity is minimally affected by exogenous
IGF-II (Nam et al., 1994).
The mechanism by which IGFBP-5 potentiates IGF actions is not well
understood. Intact IGFBP-5 adheres to fibroblast extracellular matrix (ECM) (Jones et at,
1993). When IGFBP-5 is associated with ECM, it potentiates IGF-I induced cell
proliferation by 100% (Jones et al., 1993) whereas the 21 kDa proteolytic fragment does
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not associate with ECM and does potentiate IGF action. Since IGFBP-5 affinity for
IGF-I is lowered by approximately 7 fold when associated with ECM, Jones et al. (1993)
suggested that IGFBP-5 potentiates IGF actions by fixing IGFs to the ECM with low
affinity and thereby making the IGF readily available to IGF receptors. Intact IGFBP-5 is
more potent than the proteolytic fragments in potentiation of IGF actions in bone cells
and binds directly to bone cells (Mohan et al., 1995). The IGFBP-5 potentiation of IGF
action does not involve increased IGF binding to IGF receptors. IGFBP-5 binding to
bone cells is not affected by excess of either IGF-I and IGF-II suggesting that IGFBP-5
binds to sites independent of the IGF-receptor (Mohan, et al., 1995).
IGFBP-5 production is regulated by local and systemic factors. In UMR406-1
rat osteosarcoma cells, IGFBP-5 production is increased by IGF-I, PTH, and cAMP
analogs (Conover et al., 1993). In contrast, in U2 human osteosarcoma cells, PTH has
no effect on IGFBP-5 production; however, IGF-1 increases IGFBP-5 accumulation in
conditioned medium by 10 fold compared to control, partly by inhibiting the degradation
of intact IGFBP-5 (Connover and Kiefer, 1993). In human osteoblast-like cell cultures,
IGFBP-5 production is increased by bone morphogenic (BMP)-7, IGF-I, and IGF-II by
•pretranslational mechanisms involving increased IGFBP-5 mRNA levels and by
posttranslational mechanisms involving decreased IGFBP-5 degradation (Kansaki, et al.,
1994; Knutsen et al., 1995). Retinoic acid and glucocorticoid decrease whereas
progesterone increases IGFBP-5 production (Chevalley et al., 1996; Lempeit et al., 1992;
Zhou et al., 1996).
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f. IGFBP-6
Human IGFBP-6 has a molecular weigh of 34 IcDa with 0-linked glycosylation
•sites (Bach et al., 1992; Zarf et al., 1990). Human IGFBP-6 lacks two of the 18
conserved cysteins found in IGFBPs 1-5 (Shimasalci and Ling, 1991). The distinct
property of the IGFBP-6 is that it binds to IGF-II with 20 to 100 fold higher affinity than
to IGF-I (Martin et al., 1990), suggesting that IGFBP-6 plays an important role in
modulating IGF-II actions. IGFBP-6 inhibits IGF-II stimulated DNA synthesis and
glycogen synthesis, but only minimally inhibits IGF-I stimulation (Keifer et al., 1992).
Consistent with this observation, Srinivansan et al. (1996) reported that IGFBP-6
inhibited IGF-II induced cell proliferation in MC3T3-E1, mouse osteoblasts. Like other
IGFBF's, IGFBP-6 expression is regulated by both local and systemic agents. In human
fibroblasts, IGFBP-6 is increased by TGF-13 and agents that increase intracellular cAMP
concentration such as dibutyryl cAMF', forskolin, and cholera toxin (Martin et al., 1994).
In rat ovary, IGF13P-6 production is stimulated by a combination of FSH and LH (Rohm
et al., 1993). The expression of IGFBP-6 in human osteoblasts is increased 10 fold by
retinoic acid. In addition, when human osteoblasts are treated with the combination of
retinoic acid and 1,25 (011)2D3, the IGFBP-6 expression is significantly increased
compared to treatment with retinoic acid alone (Zhou et al., 1996).
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5. Effect of progesterone on the IGF system in human osteoblasts
PG has been shown to increase bone formation in vivo (Scheven et al., 1992) and
increase human osteoblast proliferation (Lau et al., 1994; Tremollieres et al., 1992). One
of the mechanisms by which PG increases human osteoblast proliferation is through
modulation of the IGF system. PG causes an increase in IGF-II expression and induces a
transient increase in type I and type II IGF receptor mRNA levels in human osteoblasts
(Lempert et al., 1992). Pretreatment of MG63 human osteosarcoma cells with PG
increases the sensitivity of the cells to IGF-II stimulation of cell proliferation (Lempert et
al., 1992), suggesting that pretreatment with PG alters components of the IGF system and
make the cells more responsive to IGF-II. In addition to increasing IGF-II, type I, and
type II IGF receptors, PG also decreases the expression of an inhibitory IGFBP,
IGFBP-4, and increases the expression of the stimulatory IGFBP, IGFBP-5 (Lempert et
al., 1992).

E. Rationale
Although we have previously established that PG increases IGFBP-5 production
and mRNA levels, the molecular mechanism by which PG increased IGFBP-5 mRNA
levels is still unknown. IGFBP-5 is the most abundant IGFBP stored in bone and is the
only IGFBP that binds avidly to hydroxyapatite,thus functioning to fix IGFs into bone.
Since IGFBP-5 is an important regulator of the IGF system in bone and its production is
affected by PG, it is important to understand the molecular mechanisms underlying PG
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induction of IGFBP-5 production. Understanding these molecular mechanisms may help
provide a basis for understanding the mechanisms by which other regulators affect
IGFBP-5 production in human osteoblasts.
Current FDA approved treatment for osteoporosis, such as estrogen replacement
and calcitonin therapies, act by inhibiting the bone resorption component of bone
remodeling with very minimal effects on the bone formation component. With current
therapies, the net gain in bone mass in osteoporosis patients is limited. As a result, there
are few studies showing that current treatments of patients with established osteoporosis
reduce the occurrence of new fractures (Kleerekoper and Avioli, 1993). There is a need to
develop new therapeutic approaches which can effectively increase bone formation and
thus reduce the occurrence of new fractures in osteoporosis patients. Since the IGF
system plays an important role in osteoblast proliferation and IGFBP-5 enhances IGFmediated stimulation of human osteoblast proliferation, a complete understanding of
IGFBP-5 regulation in bone will provide us with an important tool to manipulate IGF
actions in the bone microenvironment. The fmdings resulting from this study will be
helpful in developing new therapeutic approaches for osteoporosis which will not only
preserve, but also increase, bone mass and reduce the occurrence of new fractures.

F. Hypothesis
The mechanism by which progesterone increases IGFBP-5 mRNA levels in
hinnan osteoblasts is transcriptional and involves the direct interaction of the activated
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progesterone receptor and specific response element(s) in the human IGFBP-5 gene
promoter.

G. Specific Aims
The specific aims that were used to guide the research described in this thesis are:
1. To determine the time course effects of progesterone treatment on
IGFBP-5 mRNA levels;
2. To determine whether progesterone affects IGFBP-5 mRNA expression
primarily through a transcriptional mechanism;
3. To isolate genomic clones containing regulatory elements for the
IGFBP-5 gene and identify the promoter region and transcriptional start sites;
4. To identify cis-acting elements in the human IGFBP-5 gene promoter
and transcription factors interacting with elements which mediate transcriptional
induction of IGFBP-5 gene expression;
5. To identify the PR receptor isoforrn required for PG-mediated
transactivation of IGFBP-5 gene in human osteoblasts.

CHAPTER TWO
II. MATERIALS AND METHODS
A. Materials
Progesterone acetate was obtained from Sigma Chemical (St. Louis, MO) and
R5020, promegestone, from Dupont NEN Research Products (Boston, MA). Human
osteogenic sarcoma U-2 OS (U2) cells (HTB96) were obtained from the American Type
Culture Collection (Rockville, MD). Dulbecco's modified Eagle's medium (DMEM) was
obtained from Mediatech, Inc. (Herndon, VA). Fe-supplemented bovine calf serum (CS)
and charcoal-dextran treated fetal bovine serum (CD-FBS) were from Hyclone (Logan,
UT). Penicillin, streptomycin and trypsin were from Gibco (Grand Island, NY).
Crystallized Bovine serum albumin (BSA) and guanidine isothiocyanate were from Fluka
(Ronkonkoma, NH). Cell culture plastic ware was obtained from Corning Incorporated
(Corning, NY).
Recombinant human IGFBP-5 cDNA (BP5/5) was the generous gift of Drs. C.
Dony and K. Lang of Boehringer Mannheim Therapeutics, Penzberg, Germany. This
cDNA was a PCR product spanning the entire IGFBP-5 coding region and was cloned
into a pUC plasmid. pMSG-CAT was obtained from Pharmacia Biotech (Piscataway,
NJ). pJFCAT1 was kindly provided by Dr. J Fridovich-Keil, Dana-Farber Cancer
Institute (Boston, MA). pGEM-3Zf(-) and pGEM-Vf(-) were obtained from Promega
(Madison, WI). Human13-actin cDNA was purchased from the American Type Culture
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Collection (Rockville, MD). pCMV-Pgal was a generous gift from California
Biotechnology Inc. (San Diego, CA)
The human genomic cosmid library was obtained from Clontech (Palo Alto, CA).
Magnagraph and NitroPure membranes were obtained from MSI (Westboro, MA).
Hybond-N membranes were obtained from Amersham (Arlington Heights, IL). INVaF"
competent bacterial cells and the pCRII plasmid were obtained from Invitrogen (San
Diego, CA). Low melting point agarose was obtained from FMC Bioproducts (Rockland,
ME). Oligodeoxynucleotides were synthesized by Integrated DNA Technologies
(Coralville, JO) and by the Center for Gene Therapy, Loma Linda University (Loma
Linda, CA). LipofectAMINE was obtained from GIBCO-BRL (Gaithergburg, MD).
The Klenow fragment of DNA polymerase I was from Promega (Madison, WI).
Vent (exo- ) was from New England Biolab Inc. (Beverly, MA). T4 polynucleotide
kinase was from Promega (Madison, WI). Restriction enzymes and buffers were from
Promega, New England Biolab Inc., and United States Biochemical Corporation
(Cleveland, OH). dNTPs, dN6(hexanucleotide), and poly (dI-dC) were obtained from
Pharmacia (Piscataway, NJ). NACS columns were obtained from GIBCO/BRL
(Gaithersburg, MD). Mermaid kits were purchased from BIO 101 Inc. (La Jolla, CA).
Wizard Miniprep, Wizard PCR DNA purification kits, and reporter lysis buffer were
obtained from Promega. Qiagen plasmid Maxi kits were obtained from Qaigen Inc.
(Chatsworth, CA). Culture dishes and polypropylene tubes were obtained from Coming
Glass Works (Corning, NY). Reporter Lysis buffer was obtained from Promega
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(Madison, WI). D-threo-1,2414C] Chloramphenicol, a-[32 P1 cl-C113, and 7432P] ATP
were purchased from ICN Biochemical, Inc. (Irvine, CA). 43211 UTP was purchased
from Dupont NEN Research Products (Boston, MA). Aprotinin and PMSF were obtained
from Sigma Chernial Company (St. Louis, MO). Leupeptin and pepstatin were obtained
from Calbiochem-Novabiochem International (San Diego, CA). PR mammalian
expression vectors pliF'1Z-A and phPR-B (Vegato et al., 1993) were provided by Dr. B.
O'Malley, Baylor College of Medicine, Houston, TX. Purified PR-A and PR-B and a
specific monoclonal antibody (AB52) which recognizes PR-A and PR-B (Onate et al.,
1994) were provided by Dr. D.P. Edwards, University of Colorado Health Sciences
Center (Denver, CO). All other molecular biology grade chemicals were obtained from
United States Biochemical Corporation (Cleveland, OH), Sigma Chemical Company (St.
Louis, MO), and Cal Biochem (LaJolla, CA).

B. Methods
1. Cell culture
U2 cells were maintained in DMEM supplemented with 10% calf serum (CS) at
37 C in a humidified atmosphere composed of 95% air and 5% CO2. In some
experiments, cells were grown 3 days in phenol-red free DMEM with 5% charcoaldextran treated fetal bovine serum (CD-FBS), transfected, and tested 48 h further in
phenol-red free DMEM with 2% CD-FBS. PG was dissolved in ethanol at 10-2 M and
was further diluted with serum-free DMEM containing 0.1% BSA before adding to the
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cells. Control cultures were treated with ethanol diluted to the same extent as for PG
treatment.

2. RNA isolation
U2 cells were plated at 5 x 105 per 100 mm2 culture dish in DMEM containing
10% CS and incubated for 24 h. The media was then replaced with serum free media
containing 0.1% BSA and incubated for 24 h. Prior to addition of PG, cells were changed
to serum free medium containing 0.1% BSA. Cells were treated with 10 nM PG for 0.5
to 24 h and total RNA was extracted using a single-step guanidinium-isothiocyanatephenol-chloroform method (Chomczynski and Sacchi, 1987). All glassware and water
were pretreated with diethylpyrocarbonate (DEPC) to destroy ribonucleases. Solutions
were made using pretreated DEPC water and then autoclaved.
For isolation of total RNA from cultured cells, media was removed and cells were
harvested by overlaying 1 ml of GIT extraction solution per 100 rnm2 dish. Cell extract
was collected in a 50-ml polypropylene tube (Coming Incorporated, Corning, NY) and
immediately stored at -80 C. For phenol chloroform extraction the following solution
were added sequentially to the cell extract, with complete mixing between each addition:
0.1 volume of 2 M sodium acetate (pH 4.0), 1 volume of DEPC water-saturated phenol
and 0.2 volume of DEPC water saturated-chloroform-IAA (49:1). The mixture was then
vortexed vigorously, incubated on ice for 15 min and centrifuged at 10,000 x g for
20 min at 4 C. The aqueous layer was transferred to a new tube, mixed with an equal
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volume of isopropanol to precipitate RNA, and stored at -20 C overnight. The RNA
pellet was collected by centrifugation at 10,000 x g for 20 min at 4 C. All residual
isopropanol was removed and the pellet was washed twice with -20 C 70% ethanol and
centrifuged at 10,000 x g for 10 min at 4 C after each washing step. All residual ethanol
was removed and the RNA pellet was air dried at room temperature for 10 min and
resuspended in approximately 50 Ill of DEPC water. The amount of RNA obtained was
determined by A260. A260/A280 ratios of RNA obtained from this method were greater
than 1.$, indicating negligible protein contamination. 100 [ig of U2 RNA was routinely
obtained from five 100 mm2 culture dishes of 80% confluent U2 cells. All resuspended
RNA was kept at -80 C.

• 3. Northern Blot Analysis
Total RNA was subjected to Northern blot analysis as described (Scharla et al.,
1993). Twenty-five 1.1g of total RNA in 10 of DEPC water was mixed with 10 µ1 of
Northern loading buffer. The mixture was incubated at 65 C for 5 min to denature the
RNA, and immediately kept on ice until loading. The RNA was fractionated on a 1.5%
agarose gel containing 6.6% 'formaldehyde and I x MOPS. Electrophoresis was
performed using 1 X MOPS as running buffer. When the xylene cyanol dye front was
near the end of the gel, electrophoresis was stopped. The gel was then transferred with
10 X SSC overnight by capillary force onto a Magnagraph membrane. RNA was fixed to
the membrane by UV cross-linking (1.6 KJ/m2) followed by baking at 80 C for 20 min.
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The membrane was prewetted with I X SSPE, stained with methylene blue solution and
washed with heated DEPC water. The stained 28S (5.1 kb) and 18S (1.9) kb ribosomal
RNA bands were used to estimate RNA transcript size and to quantitate RNA loading and
transfer. Before hybridization, the membrane was destained with 0.2 x SSPE/1% SDS.
The RNA blots were prehybridized at 42 C for 2 hour in 5 X SSPE, 50% formamide,
0.1% SDS, 5 X Denhart's solution, and 200 jig/nil denatured herring sperm DNA, then
hybridized with 2 x 105 dpm/ml of 32P-labeled probe at 42 C for 18 h in the same mixture
containing 5% dextran sulfate. The filters were then washed twice with 6 X SSPE, 0.1%
SDS at 42 C for 1 h, then once in I. X SSPE, 0.1% SDS at 42 C for 20 minutes. Equal
loading and transfer of RNA was confirmed by quantitation of methylene-blue stained
28S rRNA. Filters were exposed to Fuji-XR film with two Dupont Cronex III
instensifying screens at -80 C for 5 days. After autoradiography, the relative intensities
of the respective bands were quantitated by laser densitometry (Biomed Instruments,
Fullerton, CA) and normalized to the respective densities of the 28S rIZNA bands on
methylene blue stained filters.

4. Nuclear run-on analysis
The effect of PG on the rate of IGFBP-5 gene transcription was determined by
nuclear run-on analysis (Celeno etal., 1989). Briefly, U2 cells were treated with 10 nM
PG or with vehicle for 1 and 4 h. The cells were rinsed and scraped into ice-cold
phosphate-buffered saline and nuclei were prepared. The nuclei were then resuspended in
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transcription buffer ( 0.6 M KCi, 12.5 mM MgC12, 2.5 inN4 of ATP, CTP and GTP) and
transcription was allowed to proceed in vitro by addition of 10011Ci [32P]-UTP ( 800
Ci/mmol). Equal amounts of labeled RNA (2 x 106 dpm) were hybridized to 10 lig of
alkali-denatured plasmid DNAs which were immobilized on Hybond-N filters. The
filters were hybridized in a solution containing 10 mivi TES (2-{[tris-(hydroxymethy1)]methylamino}-ethanesulfonic acid) pH 7.4, 10 mM EDTA, 0.2% SDS, and 0.6 M NaC1
at 68 C for 48 h. After hybridization, the filters were washed twice with 6 X SSPE, 0.1%
SDS at 42 C for 30 min and once with 1 X SSPE, 0.1% SDS at 42 C for 30 min and
autoradiographed with two Dupont Cronex III intensifying screens for three days. The
relative intensity of each band on the autoradiographs was quantitated by laser
densitometry as described above.

5. Plasntid preparation
A single bacteria colony harboring plasmids or cosmids was grown overnight with
shaking at 37 C in an appropriate volume of TB or LB containing 100 lig/m1 of
amplicilin or 50 tig/m1 of kanamycin. The cells were pelleted in a 250 ml polypropylene
bottle or 50 ml disposable tube at 10,000 x g for 15 min at 4 C. Plasmid DNA was
purified using either Wizard mini-prep or Qiagen maxi kits. All plasmid DNA was stored
at 4 C.
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a. Wizard mini-preparation
To check for the presence of recombinant plasmid within a given colony and to
prepare plasmid for subcloning and DNA sequencing, small scale (3-5 ml) Wizard minipreparation kits were used as described by the manufacturer's protocol. Briefly, three ml
of bacteria cult= was pelleted and then resuspended in 200 ill of suspension solution
(50 mM Tris-HC1, pH 7.5, 10 mM EDTA and 100 lig/m1RNase A). A volume of 200 µ1
of cell lysis solution (0.2 M NaOH, 1% SDS) was added. The tubes were gently inverted
a few times, and then 200 Ill of neutralization solution (2.55 M KOAc, pH 4.8) was added
and mixed. The mixture was centrifuged in a microcentrifuge at top speed (14,000 x g)
for 5 min at room temperature. The supernatant was transferred to a fresh tube and mixed
with 1 ml of DNA purification resin by inverting the tube. The mixture was incubated at
room temperature for 1 min. The mixture was then loaded onto a mini-column attached
to a vacuum manifold. The column was washed twice with 1 ml column wash solution
(200 mM NaC1, 20 mM Tris-HCI, pH 7.5, 5 rnM EDTA). The plasmid DNA was finally
eluted with 50 ml of 65 C water.

b. Alkaline lysis preparation
This method was used to prepare cDNA probes and plasmids for nuclear run-on
analysis as described (Sambrook etal., 1989). The bacterial pellet was resuspended in
0.5 ml of LB and 5 ml of TENS buffer containing 100 gg/m1RNaseA was added. The
mixture was shaken until sticky. After addition of 2.5 ml of 3 M Na0Ac pH 5.2, the
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mixture was placed on ice. The lysate was centrifuged at 10,000 x g for 20 min at 4 C.
The supernatant was transferred to a fresh tube and 10 j.tI (10 gg/m1) RNase A was added,
mixed and incubated at 37 C for 30 min. The mixture was extracted with 10 ml of
phenol/chloroform/IAA (24:24:1) by shaking vigorously and placed on ice for 5 min.
The mixture was centrifuged at 10,000 x g for 20 min at 4 C. The supernatant was
transferred to a new tube and 1/10 volume of 3 M Na0Ac pH 5.2 and 15 ml of absolute
ethanol were added and mixed. The mixture was then placed at -20 C overnight. Plasmid
DNA was pelleted by centrifugation at 10,000 x g for 20 min at 4 C. The DNA pellet
was washed twice with -20 C 70% ethanol. The pellet was air-dried for 10-15 min, then
resuspended in sterile distilled water.

c. Qaigen maxi-preparation
For preparation of DNA for transfection and for cosmid DNA purification, a
Qaigen maxi-preparation kit was used. The purification steps were carried out according
to the protocol provided by the manufacturer. Typically, a single colony of bacteria was
resupended in 150 ml of TB broth and grown in a 37 C shaking incubator for 12-16 hr.
The bacteria suspension was then transferred to a 250 ml centrifuge bottle and centrifuged
at 10,000 •x g at 4 C for 10 min. The bacterial pellet was resuspended in 10 ml of solution
P1 ( 50 mM Tris-HC1, pH 8.0, 10 mM EDTA, and 100 ggiml RNaseA). 10 ml of
solution P2(200 mM NaOH and 1% SDS) was added, mixed by inverting the tube and
incubated at room tempera= for 5 min. 10 ml of ice-cold solution P3 ( 3.0 KOAc, pH
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5.5) was then added, mixed, and placed on ice for 20 min. The lysate was centrifuged at
30,000 x g for 30 min at 4 C. The Qaigen-500 tip was equilibrated with QBT buffer by
gravity flow (750 mM NaCi, 50 mM MOPS, pH 7.0, 15% ethanol, 0.15% Triton X-100).
After centrifugation, the supernatant was loaded onto the tip. The tip was washed twice
with 30 ml of QC buffer (1.0 NaC1, 50 mM MOPS, pH 7.0, 15% ethanol). The plasmid
was then eluted from the tip with 15 ml of QF buffer (1.25 M NaC1, 50 mM Tris-HC1,
pH 8.5, and 15% ethanol) and precipitated with 10.5 ml or 0.7 volume of isopropanol.
The plasmid DNA was pelleted by centrifugation at 13,000 x g for 30 min at 4 C. The
pellet was washed twice with 70% ethanol, air dried for 5 min, and resuspended in sterile
distilled water. This preparation typically yielded at least 3001.1g of plasmid DNA.

6. Probe isolation, labeling and purification
a. cDNA probe isolation
The human IGFBP-5 cDNA probe was prepared by EcoRI digestion of plasmid
BP5/5 and electrophoretic separation on 1.0% SeaPlaque, low melting point agarose in
1 x TBE running buffer as described (Sambrook et al., 1989). The gel was stained with
ethidium bromide and the cDNA fragments were excised from the gel. The gel
containing the cDNA fragment was melted at 70 C for 5 min and an equal volume of
DEPC-treated water was added. The gel mixture containing cDNA was stored at -20 C.

51
b. cDNA probe labeling and purification
cDNA probes were labeled by the random priming method as described (Feinburg
etal., 1983) The gel containing the cDNA fragment was melted at 70 C for 5 min. A
volume of gel containing 50-100 ng DNA was diluted in DEPC water to a volume of
31

boiled for 5 min and quickly placed on ice for 2 min. The following solutions were

added in order to the cDNA solution: 10 i.d of 5 x cDNA labeling buffer, 2 111 of
DNase-free BSA (10 mg/m1), 5 111 of a-[32P]CTP (66.7 pCi) and 2 pi of Klenow
fragment (5 U/µ1). The mixture was incubated at 37 C for 2-12 h.
Labeled DNA was purified using NACS chromatography as described by the
manufacturer. The column was hydrated with 3 ml of 2 M NaC1/TE and equilibrated
with 5 ml of 0.5 M NaCl/TE. The probe was then loaded onto the column and washed
twice with 5 ml of 0.5 M NaC1/11. The labeled probe was finally eluted with 400 IA of
0.2 M NaC1/TE. Labeling efficiency was measured by liquid scintillation counting.

c. Oligodeoxynucleotide probe labeling and purification
Single stranded or double stranded oligodeoxynucleotide probes were end-labeled
with T4 kinase as described (Ausubel et al., 1994). The 10 IA of labeling reaction
contained 50-100 ng of oligodeoxynucleotide, 1 IA of 10 x TMDSE, 200 1.iCi
y-{32P]ATP and 1 U T4 polynucleotide kin.ase. The mixture was incubated at 37 C for
1 h and labeled oligodeoxynucleotide was purified using a MERmaid kit as suggested by
the manufacturer. To 10 [11 of labeling reaction, 30 pl of High Salt Binding Solution and
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5 ill of Glassfog were added, vortexed, and incubated at room temperature for 5-15 min.
The Glassfog was then pelleted by brief centrifugation. The pellet was resuspended and
washed twice with 300 µ1 of ethanol wash solution and air-dried for 5 min. The labeled
oligodeoxynucleofide was eluted twice with 50 gi of DEPC water. The labeling
efficiency was determined by liquid scintillation counting.

• 7. Isolation of IGFBP-5 genomic clones
The human placental genomic cosmid library (pWE15) was resuspended in 5 ml
of TB and spread on three 231 cm2 BA-S supported nitrocellulose filters. The filters were
then placed on TB/Amp (TB agar containing 100 p,g/m1 amplicilin) plates (master plates).
Plates were incubated at 37 C until colonies were 0.2 mm in diameter. Nitrocellulose or
Whatman 541 replica filters were made from each master nitrocellulose filter. The
replica filters were allowed to grow on TB/Amp plates at 37 C for 6-8 h. Colonies on
replica filters were lysed and fixed by sequential soaking in: 0.5 N NaOH, and 1 M
Tris-HCI (pH 8.0)/ 1.5 M NaCl. The filters were soaked for 5 min in each solution and
finally rinsed in 2x SSC to remove cell debris. Filters were then cross-linked at
1,200 1iJ/mm2 (optimal crosslinking setting), fixed in 95 % ethanol,and baked at 80 C for
30 min in a vacuum oven.
A mixture of two oligodeoxynucleotides corresponding to regions of the
3'-untranslated region of human IGFBP-5, 5'-CCCAGGTAAGAGGAGAGGAA-3' an
5'-CTGGCTAGAGGAGGAGACA-3', were used to screen the library. These were
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labeled with r[3211 ATP using T4 Polynucleotide Kinase. Whatrnan filters No. 541 were
prehybridized in 5 X Denhart's, 0.01 M EDTA and 0.5 % SDS at 42 C for 2 h. The filters
were hybridized in 5 X SSPE, 5 x Denhart's, 0.1 % SDS, 250 tighnl of yeast tRNA, and
2-5 x 106 dpm of probe per ml of hybridization solution at 42 C overnight. Filters were
washed with 6 x SSPE/ 0.1 % SDS at 42 C for 15 min, 6x SSPE/ 0.1 % SDS at 42 C for
60 min, and 6 x SSPE/ 0.1 % SDS at 55 C for 30 min. Filters were sealed and exposed
to Fuji-XR. film at -80 °C for 24 h. 4-6 x 106 recombinant clones were screened at high
density.. All positive clones were later plated at low density and rescreened with
32P-labeled

human IGFBP-5 cDNA. The purified cosmid clones which hybridized

strongly to human IGFBP-5 cDNA were picked and rescreened. A single positive clone
was grown up in liquid culture. DNA was isolated using a Qiagen MaxiPrep kit (Qaigen,
Chatworth, CA). The cosmid DNA was digested with EcoRI, Pstl, Sad, BamHI and
HindIII, and subjected to Southern Analysis using a 32P-labeled oligodeoxynucleotide,
5'-ACTCTCGCTCTCCTGCCCCA-3', corresponding to the 5'-untranslated Exon I
region of human IGFBP-5. The cosmid fragments hybridizing to this
oligodeoxynucleotide were gel purified, subcloned into pGEM3Zf(-) (Promega, Madison,
WI) and sequenced by the dideoxy-chain termination method using a commercial kit,
Sequenase 2.0 (USB) as described by the manufacturer.
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8. Southern Blot Analysis
Southern analysis of cosmid DNA was carried out on a 1% agarose gel. The
DNA was denatured by immersing the gel in 1.0 M NaC1/0.5 M NaOH for 20 min, twice.
The gel was neutralized by soaking in 0.5 M Tris-HC1 (017.5) /1.5 M NaC1 for 20 min,
twice. DNA was transferred to MagnaGraph membranes (MSI, Nestboro, MA) using
10 X SSC as the transfer buffer. The membranes were UV cross-linked, prehybridized
(6 X SSPE, 10 X Denhart's solution, 0.5% SDS, 100 µWm' denatured herring sperm
DNA) at 42 C for 2 h, hybridized (6 X SSPE, 10X Denhart's solution, 0.5% SDS, 50%
formamide, 200 gg/m1 denatured herring sperm DNA) at 42 C for 18 h, washed and
exposed to X-ray film. For cDNA and genomic fragment probes, filters were washed
with 1 X SSC, 0.1% SDS at 42 C for 1 h, followed by 0.1 X SSC, 0.1 % SDS at 55 C for
1 h. For oligodeoxynucleotide probes, filters were washed with 6 X SSC, 0.1% SDS at
42 C for 1 h, followed by 6 X SSC, 0.1% SDS at 55 C for 1 h.

9. Primer extension analysis
Total RNA from U2 cells grown in DMEM + 10% CS was isolated and primer
extension analysis was carried out as described. Briefly, 50 j.tg of total RNA was mixed
with 5 x 104 cpm of a 32P-labeled oligodeoxynucleotide located 65 bp from the putative
transcriptional start site, (5'-GTGAAAACGGAGGAGGGGTAATGAAAAG GC-3').
The RNA mixture was then denatured at 80 C for 5 minutes and allowed to anneal at
50 C for 18 h. The primer was then extended using 200 Units of Superscript RNase
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reverse transcripta,se (GIBCO/BRL, Gaitherburg, MD) at 42 C for 90 minutes. After
•ethanol precipitation, the extended products were analyzed on an 8% urea-polyacrylamide
sequencing gel and the size was determined by comparing the band migration rate to that
of a dideoxysequencing standard on the same gel.

10. Subcloning
A 4.6 Kb EcoRI fragment which hybridized very strongly to both the IGFBP-5
cDNA and the Y-UTR region oligodeoxynucleotide was subcioned into pGEM-3Zf(-).
To prepare the vector, 10µ,g of vector was digested at 37 C for 2 hr with EcoRI as
suggested by the manufacturer, and dephosphorylated for 1 hr with calf intestinal alkaline
phosphatase at 37 C. The linearized plasmid was purified using a Wizard PCR column.
To prepare the insert, 50 gg of IGFBP-5 cosmid DNA was digested for 2 hr with EcoRI,
and separated on a 1 % low melting point agarose gel. The 4.6 kb fragment was excised
and melted by heating to 68 C for 5 min. 25 gl of agarose containing the DNA fragment,
18 ill of 10 mM Tris-HCI (pH 7.5), 5µ1 of 10 X T4 DNA ligase buffer, 1 III of purified
vector and 1 1.11 of T4 DNA ligase were mixed gently by flicking the tube. The ligation
reaction was incubated at room. temperature for at least 2 hr. At the end of the incubation
period, the reaction was remelted by heating to 68 C for 5 min and placed in a 37 C
waterbath. An aliquot of 10 IA of the ligation reation was mixed with 10 µ1 of 10 mM
Tris-HC1 (pH 7.5) prewarmed to 40 C and placed in the 37 C waterbath. For •
transformation, 2 p,1 of diluted ligation mixture and 2 111 of 0.5 M B-mercaptoethanol were
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mixed with 50 ii of INVaF competent bacteria in a 2 ml centrifuge tube. The mixture
was incubated on ice for 30 min, and heated to 42 C for I min. Immediately after heating,
450 µ1 of SOC medium was then added to the mixture. It was placed in a 37 C shaking
incubator for 1 hr. Aliquots of 50 and 200 jal of the transformed competent cell mixture
were plated on 10 ml TB plates containing 100 gg/m1 of amplicilin. X-Gal was dissolved
in dimethylformarnide and a small volume (25-30 ill) was added to the plate to the final
concentration of 50 pig/ml.
.White positive clones lacking B-galactosidase activity were picked, plasmid DNA
was isolated, and DNA was digested with EcoRI to confirm the insert size. One positive
clone was then picked, grown in 150 ml of TB/amp broth, and plasmid DNA was isolated
using the Qaigen Maxi-Prep kit. This plasmid (clone 3E3) was used for DNA sequencing
and was further subcloned for promoter analysis.

11. Polymerase chain reaction (PCR)
PCR (Innis et al., 1990) was used to facilitate the subcloning of specific regions of
the IGFBP-5 promoter. The reaction was performed in a 50 ill reaction volume
containing 1 X NEB Vent buffer, 20 ng of plasmid DNA containing the IGFBP-5
promoter, 20 pmol each of IGFBP-5 promoter sense and antisense
oligodeoxynucleotides, and 250 RM of each dNTP. The reaction was mixed and overlaid
with 50 pi of light mineral oil (USB, Cleveland, OH). The PCR reaction was performed
on a Coy thermocycler (Coy, Mn Arbor, MI). The reaction was heated to 100 C for
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5 min and cooled to the annealing temperature at 58 C for 2 min. Then, 2 limits of Vent
(exo) was quickly added to the reaction and mixed by flicking the tube. The tube was
placed back into the thermocycler and the reaction was then allowed to proceed for
32 cycles using an extension temperature of 74 C for 30 sec, a denaturation temperature
of 98 C for 1 min and an annealing temperature of 58 C for I min. At the end of the
32'' cycle, the reaction was further incubated at 74 C for 7 min . Subsequently, 50 µ.1 of
TE saturated chloroform/IAA (24:1) was used to extract the mineral oil. To access
production of the desired product, 20 IA of the aqueous phase was subjected to
electrophoresis. DNA (typically, about 1 µ1 from 50 g1PCR reaction or 20-50 ng of
DNA) in the reaction containing the desired DNA fragment was then directly subcloned
without further purification into the pCRII plasmid using a TA cloning kit (Invitrogen,
San Diego, CA) as described by the manufacture. Typically, 2 ill of PCR product, 1 µ1
(20 ng) of pCRII vector, 1 pi of 10 X ligation buffer, and 6 p.1 of distilled steriled water
was added to a 1.5 ml tube. The ligation mixture was incubated at 12 C, overnight. One
pi of ligation mixture was then used to transform INVa F' competent bacterial cells.

12. Reporter plasmid construction
Seven IGFBP-5 promoter-reporter constructs containing 753, 461, 345, 325, 252,
162, and 124 bp of IGFBP-5 of the Y-flanking region (Figure 3) were prepared using
selected restriction enzyme sites or by using PCR with specific primers to selectively
produce the desired promoter region. The fragments were subcloned into a
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chloramphenicol acetyltransferase (CAT) reporter gene vector pJFCAT1 (Fig= 4).
Detailed strategies for subcloning of each construct are described below. The name of
each subclone is shown in parentheses.
a. pCAT753 was constructed by cutting the 3E3 plasmid (See subcloning
section) with Pst I. The 776 Pst I fragment which contained 753 bp of IGFBP-5 gene
5'-flanking region and 23 bp of IGFBP-5 gene's 5'-UTR was gel purified and subcioned
into the Pst I site of pJFCAT1.
b. pCAT461 was constructed by cutting pCAT753 with Hindill to
release an insert of 490 bp containing 461 bp of the IGFBP-5 gene's 5'-flanking region.
This HindlII fragment was then subcloned into the HindIII site of pGEM-7.Zf(-) (pGH). A
clone which contained an antisense insert (pG147) was picked. Subsequently, pGH7 was
digested with BamHI and Pst I and the fragment was subcloned in the sense orientation
into the BamHI and Pst I sites of pJFCAT1.
c. pCAT345 was constructed by using specific primers of 20 bp in length
to amplify the region from +345 to -23 of the hIGFBP-5 gene. The 368 bp PCR product
was then subcioned into the pCRII vector (pCR345) using TA-cloning (Invitrogen, San
Diego, CA). The insert was flanked with Eco11.1 sites of the pCRII vector, and was
excised with E c °RI , gel purified and subcioned into the Ec oRI site of pGEM7Zf(-)
(pG345). An insert in the sense orientation was then subcioned from pG345 into the Sphl
and Pst I sites of piT'CAT1. The insert carried Xba I, Xho I, and EcoRI sites at the
5'-end.
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Figure 3. Schematic representation of hIGFBP-5 deletion promoter reporter
constructs. A partial restriction map of the human IGFBP-5 gene EcoRI fragment
containing the 5' flanking region is shown at the top. Thin vertical lines represent putative
PRE half-sites. The solid box represents CACCC sequences, the thick vertical line
represents the TATA box, and the open and striped boxes represent the 5' untranslated
region and protein coding region of Exon 1. The P sti site within Exon 1 was used to ligate
the 5' flanking region fragment into the CAT reporter gene OFCAT1. Constructs shown
below the restriction map were composed of 753, 461, 345, 325, 252, 162, and 124 bp of
IGFBP-5 5'-flanking region and contained 5, 4, 2, 2, and 0 putative PRE half-sites.
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lrbal Pid
PstI Hind III X
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II
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pCAT753
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•Figure 4. Map of promoterless vector, pJFCAT1. AAA represents the SV40
polyadenylation site trimer cassette. CAT represents the chloramphenicol
acetyltransferase gene fl represents the phage Li origin of replication. Amp r represents
the B-lactamase gene conferring amplicilin resistance. For the construction of hIGFBP-5
promoter reporter constructs, DNA fragments containing hIGFBP-5 gene 5'-flanking
regions were subcloned into the multiple cloning sites of the vector.
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d. pCAT325 was constructed the same way as pCAT345 except the PCR
product was the fragment +325 to -23 of the hIGFBP-5 gene.
e. pCAT252 was constructed the same way as pCAT345 except the PCR
product was the fragment +252 to -23 of the hIGFBP-5 gene.
f. pCAT162 was constructed by cutting pCAT461 with Xhol and Xbal.
The fragment was subcloned into the Xhoi and Xbal site of pGENI7Zf(-) (pG162). The
insert from pG162 was released by cutting with Sphl and Pstl and subcloned into the Sphl
and PsnI sites of pJFCAT1.
g. pCAT124 was constructed the same way as pCAT345 except the PCR
product was the fragment +124 to -23 of hIGFBP-5 gene.
To investigate the functionality of the TATA box at position 1052, pCAT643 was
made. pCAT643 was constructed by cutting 3E3 plasmid with Pstl The 643 bp Pstl
fragment which contained positions -1390 to -747 of the IGFBP-5 5'-flanking region was
gel purified and subcloned into Pst1 site of pJFCAT1.
For pCAT162mut, a synthetic 44-mer double stranded oligodeoxynucleotide with
overhanging Sphl ends was made. The sense strand sequence is : T-CTCTAGAAGGC
CTCTCAAAACCAAAACCCCGTGTGAGTTGCATG-3' (altered nucleotides
underlined). The oligodeoxynucleotides were annealed by boiling in a 200 ml water bath
and cooling to 22 C over 2 h. The double stranded oligodeoxynucleotide was inserted in
the sense orientation into the Sphl site of pCAT124 upstream of the IGFBP-5 5'-flanking
region. The construction of pCAT162mDi and pCAT162mPr were the same as
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pCAT162mut except a different set of oligdeoxynucleotides which had CACCC box
mutations at different positions were used. in pCAT162mDi, the sequence
•CCCACCCCCACCCC was mutated to AAAACCCCCACCCC. In pCAT162mP , the
sequence was mutated to CCCACCAAAACCCC.
The sequence and orientation of all promoter constructs used were confirmed by
sequence analysis using a commercial kit, Sequenase 2.0 (USB, Cleveland,011).

13. DNA transfection
To determine basal promoter activities of the IGFBP-5 promoter constructs,
3 x i0 U2cells were seeded in 60 mm dishes in DMEM supplemented with 10% CS.
After 18 h of incubation, cells were rinsed once with DMEM and 1.6 mi of DMEM
containing 12 of LipofectAlvIINE (GIBCO/BRL, Gaithersburg, MD) and 6 j.ig of
Qiagen purified DNA (5 lig of CAT construct + 1 lig of pCMVB-gal) was added to the
cells. The cells were incubated for 4 hr at 37 C, in 95% air-5% CO2. Medium was then •
replaced with DMEM supplemented with 10% CS and cells were incubated for 48 hr
before B-galactosidase and CAT activities were assayed. To evaluate the effect of PG on
promoter activity, U2 cells were grown in phenol-red free DMEM supplemented with 5%
CD-FBS for 72 h before transfection. Cells were then plated at 2 x i05 cellsper 60 mm
dish, and transfected as above. When progesterone receptors were overexpressed, U2
cells were transfected with 2 1.1g of phPR-A or phPR-B plasmid , 3 pg of the IGFBP-5
promoter construct and 1 14 of pCMV-Bgal. After transfection, media was then replaced
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with phenol-red-free DMEM supplemented with 2% CD-FBS for 24 h. Medium was
replaced again with phenol-red-free DMEM supplemented with 2% CD-FBS, plus
10 nM PG or solvent, for another 24 h. Cells were lyzed with reporter lysis buffer
(Promega, Madison, WI) as recommended by the manufacturer (see section below). CAT
and 13-galactosidase activities were determined as described below and CAT activity was
expressed per unit of B-galactosidase activity. Statistical analysis of differences between
groups was determined by ANOVA using Systat software (Systat Inc., Evanston, IL).

14. Cell extract preparation
At the end of the incubation period, the medium was removed and cells were
washed twice with PBS. 500 pi of 1X Reporter lysis buffer (Prornega) was added to
cover the cells in 60 mm dishes. The cells were incubated at room temperature for
15 min, scraped and transferred to a microfuge tube and placed on ice. Cell debris was
pelleted for .2 min at 4 C by centrifuging at top speed in a microfuge. The supernatant
was transferred to a fresh microfuge tube and assayed for 13-galcatosidase and CAT
activities immediately or stored at -80 C for assaying at .a later time.

15. 8-Galactosidase assay
The 13-galactosidase assay was performed as described by Rosenthal (Rosenthal,
1987). The standard assay was performed in a microtiter plate by adding 50 µ1 of a 2 X
assay buffer which contains the substrate ONPG (o-nitrophenyl-B-D-galactopyranoside)
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to 50 µI of the sample. Samples were incubated at 37 C for 30 min. The reaction was
terminated by adding 150 µ1 of 1 M sodium carbonate and A420 was determined with a
plate reader (SLT Lab Instruments, Austria). A standard curve was developed by plotting
A420 versus concentrations of B-galactosidase standard (GIBCO-BRL, Gaithergburg,

MD). The B-galactosidase activities of cell extract samples were determined from the
standard curve.

16. CAT assay
Cell extract samples were heated to 60 C for 10 min. 70.5 µ1 of 0.25 M Tris-FIC1
•(pH7.6), 0.5 µ.1 of ['4C]-chloramphenicol (0.025 pCi/m1), 5 ill of 5 lig/mln-butyryl Co A,
and 50 IA of cell extract were mixed and incubated at 37 C for 2 hr to overnight.
Subsequently, 300 ill of xylene was added to the mixture and vortexed for 30 sec. The
mixture was centrifuged at maximum speed in a microcentrifuge at room temperature for
3 min. The upper phase was then transferred to a new microfuge tube containing 100 ill
of 0.25 M Tris-HC1 (pH7.6). The mixture was then back-extracted by vortexing and
centrifuging as described above. The back extraction step was repeated twice, then,
200 µ1 of upper phase was transferred to a scintillation vial containing 2 ml of
scintillation cocktail (ScintiSafe EconoL, Fisher Chemical, Fairlawn, NJ). The
radioactivity was measured in a scintillation counter. CAT activity in each sample was
reported as CPM per unit of B-galactosidase activity.
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17. Nuclear extract preparation
U2 cell nuclear extracts were prepared as described by D gnam et al (Dignam et
al., 1983). U2 cells were plated in thirty 100 mm dishes at 4 x 105 cells in phenol-red
free DMEM containing 5% CD-FBS and incubated at 37 C in a humidified incubator
with 95% air and 5% CO2 overnight. The medium was then removed and replaced with
phenol-red free DMEM containing 2% CD-FBS and incubated for 24 hr. When cells
reached 80% confluence, thirty of 100 mm dishes were extracted. Before harvesting the
cells, medium was removed and cells were rinsed once with 1-2 nil of cold 1 X PBS.
One ml of ice cold 1 X PBS was then added per dish. Cells were harvested by scraping
with a rubber policeman, collected in a 50 ml polypropylene tube, and centrifuged at
1,800 rpm (700 x g) at 4 C for 10 min in an IEC Centra-7R refrigerated centrifuge (Fisher
Sciencetific, Pittsburgh, PA). The cell pellet was washed once in cold I X PBS and
resupended in 5 ml of ice cold Detergent lysis buffer (cells should be resuspended at
1 X 106 to3 X 106 cells per ml of buffer). The cell suspensions were then spun at
2,000 rpm (900 x g) at 4 C for 10 min in an IEC Centra-7R refrigerated centrifuge. The
supernatant was removed and cells were resuspended in 10 ml of cold RSB (see
Section C). The cell suspensions were then spun at 1500 rpm (500 x g) at 4 C for 4 min
in an IEC Centra-7R refrigerated centrifuge. The supernatant was removed and the pellet
was resuspended in a volume of extraction buffer A equivalent to the volume of the
nuclear pellet by mixing with a 1000 [Li pipette tip cut off at the end to make a larger
opening. The mixture was then transferred to an microfuge tube and a volume of
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extraction buffer B equivalent to the volume of nuclear pellet was added. Typically, 0.5
to 1.0 nil of total extract was subjected to fluffier treatment. The tube was rocked in the
cold room for 30 min. The nuclear lysate was then transferred to six 5 X 20 mm
polyallomer centrifuge tubes containing 150 µl in each tube and centrifuged in an Airfuge
Ultracentrifuge (Beckman Intrument, Palo Alto, CA) in a cold fix-angle aluminum rotor
at maximum speed (17,000 x g) for 15 min at 4 C. The supernatant was transferred to a
Slide-A-Lyzer 101( dialysis cassette (Pierce, Rockford, IL) and dialyzed for 2 hr. in
100 ml of cold buffer C in the cold room with one buffer change at the end of the first
hour. The dialysate was transferred to a microfuge tube and centrifuged at 14,000 rpm in
a microfuge in the cold room for 10 min to pellet cell debris. The supernatant was then
transferred to a microfuge tube, aliquoted into small volumes (50 µ1 per aliquot), fast
frozen in liquid nitrogen, and stored at -70 C.
The nuclear extract protein concentration was determined by Bradford protein
assay (Biorad, Richmand, VA) with BSA as a standard as described in the product's
manual. The standard assay was performed in a microtiter plate by adding 100 .ti of 40%
Bradford dye solution to the nuclear extract diluted in 100 [11 of buffer C or to BSA
standards (0.1 to 5 lig in 100 IA of buffer C). Samples were incubated at room
temperature for 5 to 10 min. The A550 was determined with a plate reader (SLT, Lab
Instruments, Austria). A standard curve was developed by plotting A550 versus
concentrations of protein standard. The nuclear extract protein concentration was
determined from the standard curve.
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18. Electrophoretic mobility shift assay (EMSA)
For the EMSA, the binding reaction contained DC binding buffer (4% glycerol,
1 mM MgC12, 0.5 mM EDTA, 0.5 mM DTT, 50 mM NaC1, and 10 InN4 Tris-HC1, pH
7.5), 0.05 mg/m1 poly (dI-dC), 1.5 µ1 (3 j.tg protein) of nuclear extract, and 1 !al
(50,000 cptn) of 32P-labeled double stranded oligodeoxynucleotides in a total volume of
20 µ1 (typically, 4il of 5 X binding buffer, 11.11 of ling/mi. poly (dI-dC), 1.5 111 of
nuclear extract, 1 IA of labeled double stranded oligodeoxynucleotides and water to the
total volume of 20111). For cold competition experiments, nuclear extract was
preincubated with unlabeled double stranded oligodeoxynucleotides for 10 min at room
temperature before the addition of the labeled double stranded oligodeoxynucleotides.
Purified PR-A and PR-B were obtained from a baculovirus expression system and
purified as described (Onate et al., 1994). To evaluate PR interactions with U2 cell
nuclear factors, different concentrations of PR proteins were preincubated with 5 p.g of
U2 cell nuclear extract protein before the addition of labeled double stranded
oligodeoxynucleotides. The reaction mixture was incubated at room temperature for
20 min and analyzed by electrophoresis using a 5% polyacrylamide-0.125% bisacrylamide gel in 0.25 x TBE pH 8.0. For supershift experiments, 1 mg of anti-PR
antibody A1352 (Onate et al., 1994) was added to the reaction and incubated on ice for an
additional 15 min before loading onto the gel. After electrophoresis, the gel was dried
and autoradiographed using Kodak X-OMAT or Biomax MS film and Dupont Cronex
III intensifying sceens.
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C. Solutions
1. Common molecular biology
a. cDNA labeling mix: 1M HEPES, pH 6.6, 0.3 M 2-mercaptoethanol,
15 units hexanucleotides, 0.2 mNI each dNTP( dATP, dGTP, dGTP, &FIT), 0.025 M
Tris-HC1, pH 8.0, 2.5 rnM MgC12.
b. 10 X TIVEDSE: 0.01 M Tris-HC1, pH 7.6, 0.1 M MgC1 , 0.05 M DTT,
1 mM spermidine and 1 mM EDTA.
c. Deionized formamide: Formamide was melted at room temperature
and deionized with 1 g AG 501 X 8 resin (BioRad) per 10 ml of formamide by stiring for
30 min at room temperature. The formamide-resin suspension was filtered twice with
Whatman #1 filter paper, aliquoted into 50 ml polypropylene tubes and stored at -20 C.
d. 50 X Denhart's solution: 1% Ficoll, 1% polyvinylpyrrolidone,
1% bovine serum albumin. The solution was filtered through a disposable 0.22 micron
Nalgene filter.
e. DEPC water: 0.1% diethlyl-pyrocarbonate (DEPC) was added to
double-distilled water to 0.1% v/v, shaken, and incubated for at least 1 hr. The DEPC
treated water was then autoclaved.
f. Luria broth (LB): 0.1% Bacto-tryptone, 0.05 % bacto-yeast extract,
0.1% NaCi, pH 7.1. This was autoclaved, then cooled to room temperature before use.
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g. Terrific broth (TB): 1.2% Bacto-tryptone, 2.4% yeast extract and
0.4% glycerol, potassium phosphate, pH 7.4. This was autoclaved, then cooled to room
temperature before use.
h. Methylene blue staining solution: 0.02% methylene blue and 0.3 M
sodium acetate, pH 5.5. The solution was stored in an amber bottle to protect from light.
i. 10 X MOPS: 0.2 M 3-(N-morpholino) propanesulfonic acid, 5 mM
sodium acetate, 5 mM EDTA, pH 7.0. This was autoclaved, then cooled to room
temperature before use.
j. Northern sample loading buffer: 720 xl deionized formamide, 320 gl
10 X MOPS, 260 gl 37% stock deionized forrnamide solution, 100 il glycerol, 4 mg
bromphenol blue, 4 mg xylene cyanol and 100 jd DEPC water.
k. Pre-GIT extraction solution: 4 M guanidium thiocyanate, 0.025 M
sodium citrate and 0.5 % N-lauryl sarcosine.
1. GIT extraction solution: 360 µ.1 of 2-mercaptoethanol per 50 ml preGIT extraction solution, added within 24 hr of use.
m. 10 X NEB Vent Buffer: 0.1 M KC1, 0.2 M Tris-11C1, pH 8.8, 0.1 M
(NE14) SO4, 0.02 M MgSO4, 1% Triton X-100.
n. 20 X SSPE: 3.6 M NaCi, 0.03 M NallPO4, 0.02 M EDTA, pH 7.4,
autoclaved.
o. 20 X SSC: 3.0 M NaC1 and 3.0 M sodium citrate, pH 7.0, autoclaved.
p. 50 X TAE: 2 M Tris-acetate pH 8.0 and 0.05 EDTA, autoclaved.
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q. 10 X TBE: 0.4 M Tris-HC1, pH 8.0, 0.4 M boric acid and 0.012 M
EDTA, pH 8.3, autoclaved.
r. TE buffer: 0.01 M Tris-HC1, pH 8.0, 1 mM EDTA, autoclaved.
s. TENS: 0.1 M NaOH, 0.01 M Tris-HC1, pH 8.0, 1 mM EDTA and
0.1 % SDS.
t. B-Galactosidase assay 2 X buffer: 120 mM Na2HF'04, 80 mM
NaH2HPO4, 2 mM MgC12, 100 mM B-mercaptoethanol, 1.33 mg/mi. ONPG.

2. Solutions for nuclear extract preparation
a. IX PBS: 137 mM NaC1, 2.7 mM KC1, 4.3 mM Na2HPO4 L47 mM
KH2PO4, pH 7.4, sterile filtered.

b. 'nal buffer: 50 mM Tris-HCI pH 7.5,50 mM KCi, and 15 mM
MgC12, autoclaved.
•

c. Aprotinin stock: 2 mg/ml in water, aliquoted in 1 ml volume and

stored at -20 C.
d. Leupeptin stock: 4 mg/ml in water, aliquoted in I ml volume and
stored at -20 C.
e. Pepstatin stock: 2.5 mg/ml in methanol, aliquoted in 1 ml volume and
stored at -20 C.
f. PMSF stock: 15 mg/ml (100 pM) in isopropanol aliquoted in 1 ml
volume and stored at 4 C.
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g. Detergent lysis buffer: 50% TKM, 30% sucrose, and 0.5% NP-40.
For each 5 ml of the buffer, 5 jd each of pepstatin stock, aprotinin stock, and leupetin
stock, and 25 111 of PMSF stock is added immediately before use.
h. RSB buffer: 0.1 M Tris, pH 7.4, 10 mM NaC1, and 3 mM MgC12. For
each .5 nil of the buffer, 5 ill each of pepstatin stock, aprotinin stock, and leupetin stock,
and 25 µ1 of PMSF stock, is added immediately before use.
i. Buffer A: 20 mM HEPES, pH 7.9, 2 mivi MgC12, 200 mM NaC1,
0.2 mM. EGTA, 0.2 mM EDTA, 0.5 mM DTT, 5% glycerol, 0.5 mM PMSF, 2 pg/m1
aprotinin, 5 tig/mlleupeptin, 5 gg/m1pepstatin.
j. Buffer B: Same as buffer A except that it includes 600 mM NaCl.
k. Buffer C: Same as buffer A except that it includes 100 mM NaCl, and
20% glycerol.
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III. RESULTS
A. Effects of PG on hIGFBP-5 mRNA Levels
U2 cells were selected for this study because both IGFBP-5 expression and
transfection efficiency were higher in this cell type than in other human osteoblast-like
cell lines. 10 nM PG treatment for 6 h increased IGFBP-5 mRNA levels to 240% of
control (Figure 5). Stimulatory effects of PG on steady state IGFBP-5 mRNA levels
were difficult to demonstrate after longer treatment times since IGFBP-5 mRNA levels
increased with time in control cultures such that the relative effect of PG after 24 h of
treatment was less than 150% of control (Figure 5). In time course studies, 10 nM PG
treatment for as little as 2 h increased IGFBP-5 mRNA to 150-200% of control. This
stimulatory effect of PG on IGFBP-5 mRNA levels was not unique to U2 cells or related
to the transformed phenotype. In previous work (Lempert et al., 1992) showed that
treatment of MG63 human osteosarcoma cells and normal human osteoblast-like cells
with 10 nM PG for 2 h increased IGFBP-5 mRNA levels to 270% and 500% of control,
respectively.
To determine if the effect of PG to increase IGFBP-5 mRNA accumulation
required new protein synthesis, U2 cells were treated concurrently with 10 nM PG and
5 ilg/mlcycloheximide. Cycloheximide did not alter the PG stimulated increase in
IGFBP-5 mRNA levels, suggesting that PG did not induce production of other proteins
which were required for subsequent induction of IGFBP-5 expression (Figure 6). These
data support the hypothesis that PG directly induces IGFBP-5 gene transcription.

Figure 5. Time course of increased IGFBP-5 mRNA levels after PG treatment. U2 cells were treated with 10 ri.M PG or
vehicle control for the time intervals indicated. Total RNA was extracted and subjected to Northern analysis. The amount of 25
gg of total RNA was run in each lane. The relative densities of IGFBP-5 mRNA transcript bands on the autoradiographs are
indicated as % control measured by laser densitometry.

Figure 6. Effect of cydoheximide on the PG stimulated increase in IGFBP-5 steady state mRNA levels. U2 cells were
treated concurrently with 10 nIVI PG and 5 lig,/m1 cycloheximide, a protein synthesis inhibitor, for 4 h prior to RNA extraction.
The relative densities of IGFBP-5 mRNA transcript bands on the autoradiographs are indicated as % control measured by laser
densitometry. Cyclohe)dmide, at concentrations which inhibit 90% of new protein synthesis, minimally altered the PG
stimulated increase in IGFBP-5 mRNA levels.
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B. Effect of PG on the Rate of hIGFBP-5 Gene Transcription
The effect of PG to increase IGFBP-5 mRNA levels within 2 h suggested that PG
increased the rate IGFBP-5 gene transcription. To further investigate the mechanism for
PG action, the effect of PG on the rate of IGFBP-5 gene transcription was determined by
•nuclear run-on analysis. Nuclear RNA transcripts (hnRNA) were extracted after
treatment with 10 nM PG for a period of time and transcription was allowed to proceed in
isolated nuclei in the presence of [32P]-UTP. The labeled RNA was then hybridized to
•cDNA plasmids of genes of interest which were immobilized on a nylon membrane.
Genes which were transcribed at higher rates bound more labeled hnRNA to the
immobilized cDNA plasmids and demonstrated stronger band intensities. The rates of
•gene transcription were then estimated by comparison of band intensities of the genes of
interest to those of a gene which was constitutively expressed (B-actin). PG treatment for
I h increased IGFBP-5 gene transcription to 400% of control while the rate of B-actin
gene transcription was not significantly affected (Figure 7). After 4 h of PG treatment,
the IGFBP-5 transcription rates in both the treated and control groups were less compared
to that found after I h of PG treatment.

C. Isolation of the hIGFBP-5 Gene
To begin to determine the mechanism by which PG increased the rate of IGFBP-5
gene transcription, the human IGFBP-5 (hIGFBP-5) gene was cloned and the proximal
region sequenced. From 4-6 x 105 gemomic cosmid clones, one clone was isolated which
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hybridized intensely to both the 3'-untranslated region oligodeoxynucleotide mixture
(Figure 8). This cosmid contained an insert of approximately 50 kb. The insert was
characterized by Southern analysis using hIGFBP-5 cDNA or an oligodeoxynucleotides
corresponding to +28 to +48 of hIGFBP-5 cDNA as described in Methods section
(Figure 9). Southern analysis and sequencing suggested that this insert contained over
3 kb of 5'-flanking sequence, all of the coding region, and part of the 3'-untranslated
region of Exon 4. Southern analysis of both genomic DNA and the 50 kb cosmid insert
demonstrated a 4.6 kb EcoR1 restriction fragment which hybridized to the human
IGFBP-5 cDNA and to an oligodeoxynucleotide probe corresponding to the
5'-untranslated region (Figure 9). This evidence suggested that the gene fragment was
likely to contain the proximal 5'-flanking region and promoter. Therefore, this EcoRI
fragment was subcloned into pGEM3Zf(-) for sequencing. The restriction map of the
subclone is shown in Figure 10.

D. Structural Analysis of the hIGFBP-5 Gene
To verify that the 4.6 kb EcoRI genomic fragment contained regulatory regions of
the hIGFBP-5 gene, the fragment was sequenced beginning from the first exon. The
hIGFBP-5 sequence from position -461(relative to start of transcription) through the first
exon was reported previously (Allander et al., 1994), and is identical to the sequence
obtained.

Figure 7. PG increases IGFBP-5 gene transcription in U2 cells. U2 cells were treated for 1 h with 10 tiA4 PG or vehicle
32P]UTP.
control and nuclei were isolated. Transcription in 107 isolated nuclei per group was continued in the presence of [
P-labeled hriRNA was hybridized to immobilized human B-actin cDNA, human IGFBP-5 cDNA and pBluescript vector control
32
DNA as described in Methods. The relative densities (mean of two replicates in each experiments) of 32P1abeled hnRNA
binding to target DNAs were measured by laser densitometry of the autoradiographs and are expressed as % of vehicle treated
control.

costnid clones
Figure 8. Diagram demonstrating isolation of the hIGFBP-5 gene. To isolate hIGFBP-5 clone, 4-6 x 105
from a human placental library were plated at high density and screened with a mixture of oligodeoxynucleotides corresponding
-UTR) region of the liEGFBP-5 cDNA sequence (Methods). Positive clones from the first
to sequences in the Y-untranslated (31
step (top left panel) were replated and screened at high density. Positive clones from the second step (top right panel) were
replated and screened again at low density. Positive clones from the third step (lower right panel) were replated and screened at
low density (lower left panel) until all colonies on the plate hybridized strongly to the mixture of MGFBP-5 Y-UTR
oligodeoxynucleotides.

Figure 9. Restriction analysis of the hIGFBP-5 cosmid clone. Cosmid DNA from the positive clone was isolated, digested
P-labeled hIGFBP-5 cDNA (left panel) or
with restriction enzymes, and subjected to Southern Analysis using a 32
oligodeoxynucleotide corresponding to +28 to +48 of human IGFBP-5 cDNA (right panel) as probes. Names of restriction
enzymes used are shown above each lane. The positions and sizes (bp) for Hine III digested 0(174, and Hind III digested
32P-labeled hIGFBP-5 5'-UTR was
DNA marker are indicated. The 4.6 kb EcoRl fragment which hybridized strongly to the
subcloned into pGEM3Zf(-) and sequenced.
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The sequence from 4390 to -462 that is present in the EcoRI fragment, which was not
present in the Ilind111-Pstl fragment reported previously (Al'ander et al., 1994), has not
been previously reported. The 5'-flanking region contains a TATA box and CAAT box,
multiple progesterone response elements (PREs) and other putative response elements
(Figure 10). A potential transcription initiation site (gtAgtc where A is the start of
transcription) resides 33 nucleotides from the proximal TATA box. A putative second
distal promoter complete with TATA (-1125 to -1119) and CAAT (-1187 to -1183) boxes
was identified with a potential transcription initiation site (tcAgga) 31 nucleotides
downstream of the TATA box (-1088 to -1083).
The transcription start site of the human IGFBP-5 promoter in breast cancer cells
was identified previously as 33 nucleotides 3' from the TATA box corresponding to the
proximal TATA box of the EcoRI fragment that we analyzed (Allander et al., 1994). To
determine whether this site was also used to initiate transcription in human osteoblasts,
primer extension analysis of U2 cell RNA was carried out. An end-labeled
oligodeoxynucleotide corresponding to a location in the hIGFBP-5 5'-untranslated region,
65 nucleotides from the putative start site, was hybridized to 50 µg of U2 cell total RNA.
The fragments that were produced by extension with reverse transcriptase were separated
on an 8% polyacrylamide gel containing sequencing standards in adjacent lanes. This
analysis revealed a single band 33 nucleotide from the TATA box, which is the same
result obtained by Allander et at No evidence was found supporting use of the putative
distal promoter and transcription start site at position -1052 in human osteoblasts.
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E. Structural Comparison of Human, Rat, and Mouse IGFBP-5 Promoters
As shown in Figure 10, the 1,390 bp 5'-flanking region of human IGFBP-5 was
compared to the reported 936 bp of rat (Zhu et al., 1993) and 1065 bp of mouse (Kou et
al., 1994) IGFBP-5 5'-flanking regions. The three IGFBP-5 proximal promoter
sequences are 70% similar, with the greatest sequence similarity near the transcription
initiation site and identical consensus sequences for the proximal promoter elements. The
three sequences contain, in the same relative positions, identical TATA (-33) and CAAT
(-73) boxes and a pair of ovelapping putative AP-2 binding sites (Becker et al., 1987;
Faisst and Meyer, 1992) at position -148 and -139. Within the AP-2 binding sequences
are two adjacent CACCC boxes (Bassel-Duby et al., 1992; Bassel-Duby et al., 1994;
Chen et al., 1994; Kim et al.., 1992; Miller and Beiker, 1993; Schule et al., 1988; Wang et
al., 1993).
The consensus glucocorticoidiprogesterone response element (GRE/PRE) is
composed of two hexameric half-sites arranged as a palindrome with a 3-base pair spacer,
GGTACANNNTGTTCT (Lieberman et al., 1993). A computer analysis of 1392 bp of
the hIGFBP-5 gene 5'-flanking region revealed the absence of consensus GRE/PRE
sequences. However the hIGFBP-5 promoter contains five putative GRE/PRE half sites
at position -528, -392, -333, -215 and -193, which have strong sequence similarity to the
hexanucleotide motif 5'-TGITCT-3' of the MMTV promoter and 5'-TGTTCA-3' of the
uteroglobin gene promoter (Bailly et A, 1986; Beato et al., 1989). Although GR and PR
do not bind to GRE/PRE half-sites as effectively as to the palindromic GRE/PRE
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consensus sequence, clusters of GRE/PRE half-site sequences in the MMTV, uteroglobin
and other promoters are functional. GR and PR bind to the half-sites and effectively
mediate ligand dependent transactivation through synergistic interactions between the
mutiple half-sites (Bailly et al., 1986; Beato et al., 1989; Lieberman et al., 1993).
PRE half-site sequences are also present in the rat and mouse IGFBP-5 promoters
(Figure 10) and in the rat IGFBP-1 promoter (Goswami et al., 1994), supporting the
hypothesis that these sequences may be functionally significant. The rat IGFBP-5
promoter contains, at the same relative position as the human IGFBP-5 promoter, two
PRE hexameric half-site sequences which are identical and one which is similar (five of
six nucleotides) to the human. The mouse IGFBP-5 promoter contains two PRE half-site
sequences which match the corresponding human PREs in five of six nucleotide
positions. The rat IGFBP-1 promoter contains a single 12 bp imperfect GRE/PRE
sequence which binds to the glucocorticoid receptor protein in DNA footprinting
experiments (Goswami et al., 1994). Nine of the 12 nucleotides that comprise the 5'- and
3'-half-sites of the rat IGFBP-1 GRE/PRE sequence (position -7 to -5 and position +2 to
+7) are identical to human IGFBP-5 PRE-4 and PRE-5 sequences at -215 and -193
(Figure 10).

F. Functional Analysis of the hIGFBP-5 Promoter
To determine whether the putative hIGFBP-5 promoter functions in human
osteoblasts, CAT reporter constructs containing a 776 bp Pst1 fragment (pCAT753) and a
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484 bp HindIII1Pstl fragment (pCAT461) were prepared. Both constructs contain the
transcriptional start site, 23 bp of 5'-untranslated region, and the putative overlapping
AP-2/CACCC sequences. The pCAT753 construct contains five putative PRE half-sites
and pCAT461 contains four. Subconfluent U2 cells were transiently transfected with the
sense reporter construct, antisense construct, or the pJFCAT1 promoterless control
vector. When U2 cells were transfected with pCAT753 or pCAT461 sense construct and
incubated for 48 h, CAT activity increased to 620 and 730% respectively, of CAT activity
in cells transfected with pJFCAT1 promoterless construct (Figure 11). CAT activity from
antisense construct was the same as pJFCAT1. These results suggest that the sequence
from -461 to +23 contains a functional promoter.
To investigate whether the putative TATA box at position -1052 functions in
human osteoblasts, a CAT reporter construct containing a 643 bp Pst I fragment from
positions-1390 to -747 (pCAT643) was prepared. Subconfluent U2 cells were transiently
transfected with sense reporter construct, antisense reporter construct or the pJFCAT1
promoterless control. No increase in CAT activity was observed when cells were
transfected with pCAT643 compared to pJFCAT1 promoterless control. Therefore, these
results suggest that the TATA box at position -1052 does not function in human
osteoblasts.
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G. PG induction of the hIGFBP-5 Promoter is PR Isoform Specific
To evaluate whether the 51 -flanidng region of the hIGFBP-5 gene mediates PG
induction of transcription, PG induction of CAT expression from pCAT753 and
pCAT461 was determined. To reduce basal steroid exposure and optimize
responsiveness to PG, U2 cells were maintained for 72 h in phenol red-free DMEM
supplemented with 5% charcoal-dextran treated fetal bovine serum (CD-FBS) before
transfection. Cells were co-transfected with pCAT753 (or pCAT461) and pCMV-B-gal,
then incubated 48 h in phenol red-free DMEM supplemented with 2% CD-FBS in the
absence or presence of 10 nNI PG.
In several replicate experiments with pCAT753, 10 nM PG increased CAT
activity to 140% of control (p<0.01, Figure 12). PG activated transcription of pCAT461
to the same degree as transcription of pCAT753, suggesting that the PRE at position -528
and other sequences distal to -461 were not essential for PG stimulation of hIGFBP-5
promoter activity. The small but significant effect of PG on IGFBP-5 promoter activity
suggested that PG might induce IGFBP-5 transcription by a PR-dependent mechanism
utilizing the low levels of endogenous PRs in the U2 cells. Alternatively, PG might
induce IGFBP-5 transcription by a PR-independent mechanism. To determine whether
PG induction of IGFBP-5 transcription involves PR's, we cotransfected U2 cells with PR
expression vectors.
PRs are expressed in various cells as two different isoforms which are transcribed
from separate promoters in the PR gene (fora et al., 1988). The B-receptor isoform
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(PR-B) is 933 amino acids in length and the A-receptor isoforrn (PR-A) lacks 164 amino
acids at the N-terminus. To determine whether PG induction of IGFBP-5 transcription is
mediated by PRs and to define the specificity of the PR isoform, U2 cells were transiently
transfected with either human PR-A or PR-B expression vectors, phPR-A and pliPR-B
(Vegato et al., 1993), along with pCAT753 and pCMV-B-gal. When U2 cells were cotransfected with expression vector phPR-A , along with pCMV-B-gal, PG reproducibly
increased hIGFBP-5 promoter activity to 200-300 % of control, significantly higher than
in cells transfected with vector alone (Figure 13). The same result was obtained after
treatment of co-transfected cells with promegestone (R5020), a non-metabolizable
progestin analog. The optimal DNA concentration for phPR-A was 2 lag per 60 mm dish.
In cells transfected with phPR-B DNA (1 to 5 lig per 60 mm dish), PG did not increase
IGFBP-5 promoter activity more than cells transfected with vector alone. Overexpression
of PR-B, therefore, did not increase hIGFBP-5 promoter activity (Figure 13). In
addition, when equal amounts of phPR-A and phPR-B were mixed and co-transfected
with pCAT753 and pCMV-13-gal, PG increased hIGFBP-5 promoter to the same extent as
overexpressing PR-A alone, 200-300 % of control. This result suggests that PR-A acts as
a dominant positive regulator of PG induced hIGFBP-5 gene transcription.
To ensure that functional PR's were expressed from phPR-A and particularly from
pliPR-B in U2 cells, cells were transiently transfected with either phPR-A or phPR-B
together with the MMTV promoter-reporter construct pMSG-CAT and were
subsequently treated with PG or vehicle control.
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Figure 11. Demonstration of hIGFBP-5 promoter activity. DNA fragments containing
461 (pCAT461) or 753 bp (pCAT753) of hIGFBP-5 5'-flanking region were used to drive
expression of the CAT reporter gene and are compared to promoterless control,
pJFCAT1. The promoter-reporter constructs were transiently transfected into U2 cells
and incubated in DMEM supplemented with 10% CS as described in Methods. CAT
activity was measured 48 h after transfection, normalized to B-galactosidase activity from
respective groups, and expressed as % of control (cells transfected with pJFCAT1). Bar
graphs represent mean CAT activity ± SD. In both pCAT461 and pCAT753 groups, CAT
activities were significantly greater than basal (p<0.001), as determined by ANOVA.
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Figure 12. PG increases IGFBP-5 promoter activity. The promoter-CAT reporter
construct, pCAT753, was transiently transfected, along with pCMVB-gal, into U2 cells
and incubated in phenol-red free DMEM supplemented with 2% CD-PBS in the absence
or in the presence of 10 nM PG as described in Methods. CAT activity was normalized to
B-galactosidase activity from respective groups, and expressed as % of control (cells
transfected with pWCAT1), mean ± SD of five experiments. PG treatment significantly
increased CAT activity (p<.01), as determined by Student's paired t-Test and by KniskalWallis non-parametric test.
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Figure 13. PG induction of IGFBP-5 promoter activity is receptor type specific. U2
cells were transiently transfected with 3 gg of pCAT753 plus 2 j.tg of PR expression
vector alone (without PR coding sequence), phPR-A or phPR-B. After transfection, cells
were treated with 10 nM PG for 24 h. CAT activity was normalized to B-galactosidase
activity and expressed as % of control ( cells transfected with CAT reporter construct plus
vector alone, treated with solvent control). Values are mean ± SD of at least three
independent experiments.
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Figure 14. Functional PR isoforms are expressed from expression vectors in U2
cells. U2 cells were transiently transfected with 3 lig of pMSG-CAT, which contains the
mouse mammary tumor virus long terminal repeat, plus 2 [kg of PR-A or PR-B expression
vector ,phPR-A or phPR-B, respectively. After transfection, cells were treated with 10
nM PG for 24 h. CAT activity was normalized to B-galactosidase activity and expressed
as % of respective control groups ( cells transfected with CAT reporter construct plus
phPR-A or phPR-B, treated with solvent control). Values are mean ± SD of at least three
independent experiments.
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This construct contains a functional PRE from the MMTV long terminal repeat. Both
phF'R-A and phPR-B conferred PG inducibility to the MMTV promoter to 170% and
2000% of control respectively (Figure 14), demonstrating that PR-B was effectively
expressed in U2 cells. This result was consistent with a previous report (Fora et al.,
1988) demonstrating that PR-B was a more efficient activator of the MMTV promoter
than was PR-A. In contrast to the relative effects on the MMTV promoter, PG
reproducibly increased hIGFBP-5 promoter activity to 200-300% of solvent treated
control in U2 cells overexpressing PR-A (Figure 13) but did not increase IGFBP-5
promoter activity in cells overexpressing PR-B. These data support the conclusion that
PG induction of hIGFBP-5 promoter activity is mediated by PR-A but not PR-B.

H. Identification of hIGFBP-5 Promoter Sequences which Confer PG
Responsiveness-the Progesterone Dependent Response Element (PDRE)
As a first step to determine whether the putative PRE half-sites identified in the
hIGFBP-5 proximal promoter mediate effects of PG on hIGFBP-5 transcription, a series
of 5'-deletions were made which contained progressively fewer PRE half-site sequences.
Constructs contained 753, 461, 345, 325, 252, 162, and 124 bp of the hIGFBP-5
5'-flanking region with 5,4, 3,2 , 2 and 0 putative PRE half-sites, respectively (Figure
3). Basal promoter activity of each construct determined in cells maintained in DMEM
plus 10% calf serum was 300% to 2000% of the promoterless control group (Figure 15).
PG induction of activity from each hIGFBP-5 promoter deletion construct was
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determined in cells pre-cultured in DMEM ±5% CD-FBS, cotransfected with phPR-A,
pCMV-ii-gal and the deletion construct, then changed to DMEM ±2% CD-FBS with
solvent or 10 nM PG. Basal promoter activities in these conditions were lower than when
cells were in 10% CS. In multiple experiments PG reproducibly increased promoter
activity from all deletion constructs from pCAT753 to pCAT162 by 200-300% of the
respective solvent treated controls (Figure 16). However, PG failed to increase CAT
activity in cells transfected with pCAT124 which contained only the CAAT and TATA
boxes, although pCAT124 and pCAT162 had similar levels of basal promoter activity.
These data suggest that (1) none of the putative PRE half-sites were required for liganddependent transactivation of the hIGFBP-5 promoter and (2) the element between -162
and -124, which contains two tandem CACCC box sequences (Chen et al., 1994; Direks
et al., 1983; Kim et al., 1992), may confer PG responsiveness to the hIGFBP-5 promoter.
The CACCC box sequence is an important promoter element required for efficient
and accurate gene expression in the B-globin gene (Direks et al., 1983). In addition, the
CACCC box can interact with several transcription factors including the retinoblasotoma
control element (RCE) binding protein, myocyte nuclear factor, and other
CACCC-binding proteins (Bassel-Duby et al., 1994; Faisst and Meyer, 1992; Miller and
Beiker, 1993; Wang et al., 1993). CACCC-binding proteins can either bind directly to
the CACCC box or interact with other transcription factors and bind as a complex
(Schule et al., 1988).
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To determine whether the CACCC sequences between position -162 and -124 are
the critical elements that are required for PG stimulation of hIGFBP-5 promoter activity,
both (pCAT162mut), distal (pCAT162mDi), or proximal (pCAT162mPr) CACCC
sequences in pCAT162 were mutated from CCCACCC to AAAACCC. PG induction
determined in cells pre-cultured in DMEM + 5% CD-FBS, co-transfected with phPR-A,
pCMV-B-gal, and pCAT162 mutant constructs or wild type pCAT162, then changed
medium to DMEM ±2% CD-FBS with solvent or 10 nM PG. In multiple experiments,
PG increased pCAT162 and pCAT162mDi promoter activities but failed to increase
pCAT162mut and pCAT162mPr promoter activities (Figure 17). Thus, mutation of the
proximal CACCC box at position -139 abolished PG transactivation hIGFBP-5 promoter
activity. These data provide strong evidence that the proximal CACCC sequence at
position -139 is required for PG dependent transactivation of hIGFBP-5 promoter.
activity.

I. CACCC Binding Sequence in the hIGFBP-5 Promoter
To determine whether U2 cell nuclear proteins interact with the PG responsive
hIGFBP-5 promoter sequence -124 to -162, electrophoretic mobility shift assays (EMSA)
were performed. Double stranded synthetic oligodeoxynucleotides were prepared
corresponding to the wild type hIGFBP-5 promoter sequence from -155 to -128, termed
the hIGFBP-5 Progesterone Dependent Responsive Element (BP5-PDRE). BP5-PDRE
oligodeoxynucleotide was end-labeled and incubated with 3 [ig of nuclear extract from
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U2 cells that had been incubated in phenol red free DivIEM supplemented with 2%
CD-PBS for 48 h. Analysis by EMSA resulted in a reproducible set of shifted bands
(Figure 18A). To determine the specificity of this nuclear factor binding, nuclear extract
proteins were incubated with labeled BP5-PDRE in the presence of excess concentrations
of the unlabeled oligodeoxynucleotide BP5-PDRE or oligodeoxynucleotides containing
functional CACCC box core motif sequences from other promoters (cold competition):
RCE sequences from the TGF-B and c-fos promoters, and the MNF binding site sequence
from the myoglobin promoter. Cold competition was also assessed with
oligodeoxynucleotides corresponding to the consensus AP-2 binding site sequence from
the metallothionein-IIA promoter (Williams et al., 1988) and the consensus Spl binding
site sequence from Simian virus 40 (Briggs et al., 1986) because the transcription factor
Spl had been shown to bind to an RCE (Chen et al., 1994), and a CACCC box has been
shown to function as an alternate AP-2 response element (Fthsst and Meyer, 1992). The
oligodeoxynucleotides were all approximately the same length. The sequence, promoter
source, and reference of each oligodeoxynucleotides are described in Table 1. As shown
in Figure 18A, a 50 fold molar excess of unlabeled BP5-PDRE specifically competed
with labeled BP5-PDRE for binding to U2 cell nuclear protein. At 50 fold excess molar
ratio of unlabeled DNA to labeled BP5-PDRE DNA, consensus AP-2, Spl, and RCE
sequences did not compete as effectively with labeled BP5-PDRE for binding. However,
25, 50 and 100 fold molar excess of the MNF binding sequence did effectively compete
with labeled BP5-PDRE for nuclear protein binding (Figure 18B). In comparison, 50 and
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100 fold molar excess of consensus AP-2 did not effectively compete for binding
(Figure 19). These results suggest that nuclear protein(s) which bound to the BP5-PDRE
DNA sequence were not transcription factors AP-2, Spl, or RCE binding proteins but
could be factors related to MNF. MNF is a novel winged-helix transcription factor that
binds to a CACCC motif-containing response element in the human myoglobin promoter
(Bassel-Duby et al., 1992; Bassel-Duby et al., 1994; Faisst and Meyer, 1992). The
myoblobin MNF binding site contains a single CCCCACCCC sequence which is
identical to the CCCCACCCC sequence in the hIGFBP-5 promoter that confers PG
responsiveness.
To further define DNA sequences in the BP5-PDRE which were required for
binding of nuclear proteins, both CCCACCC sequences between -147 to 439 were
mutated to AAAACCC (BP5-PDREm1, Table 1). This is the same mutation that
eliminated PG responsiveness in the hIGFBP-5 promoter-reporter construct,
pCAT162mut. As shown in Figure 18B, BP5-PDREm1 did not compete with labeled
BP5-PDRE oligodeoxynucleofides, supporting the conclusion that CACCC sequences in
the BP5-PDRE sequence are required for nuclear factor binding. To determine ifone or
both tandem CACCC boxes in the hiGFBP-5 promoter bound to nuclear factors, the
CACCC sequences were individually mutated from CCCACCC to CCAACCC. Mutation
of both distal and the proximal (3P5-PDREm2, Table 1) or mutation of only the
proximal CACCC sequence (BP5-PDREm4, Table 1) eliminated competition with wild
type labeled BP5-PDRE for nuclear factor binding (Figure 18B). However, mutation of
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only the distal CACCC sequence (BP5-PDREm3, Table 1) did not eliminate the ability of
the oligodeoxynucleotide to compete with labeled BP5-PDRE for nuclear factor binding,
suggesting that the distal CACCC sequence is not essential for forming the DNA-protein
complexes observed by EMSA. This fmding is consistent with the mutation of pCAT162
which demonstrated that only the proximal CACCC box at position -139 was required for
PG transactivation of hIGFBP-5 gene transcription. Together, these data strongly suggest
that the proximal CACCC box at position -139 is essential for the binding of U2 cell
nuclear protein(s) and PG transactivation of hIGFBP-5 gene transcription.

J. PR-A Interaction with Nuclear BP5-PDRE Binding Protein(s)
Deletion of region -162 to -124 and mutation of the CACCC sequences within
this region abolished PG responsiveness of the hiGFBP-5 proximal promoter. In
addition, the BP5-PDRE oligodeoxynucleotide corresponding to this region of the
promoter bound to U2 cell nuclear protein(s). These results suggest that PR-A could
either directly bind to the BP5-PDRE or interact with nuclear protein(s) which bind to the
BP5-PDRE. To test these possibilities, EMSAs were carried out to examine the binding
of purified baculovirus-expressed human PR-A to the BP5-PDRE. The functionality of
the PR-A preparation was first tested by EMSA with a consensus progesterone response
element oligodeoxynucleotide MMTV-PRE) from the mouse mammary tumor virus
promoter (El-Ashry et al., 1989) and the PR monoclonal antibody, AB52 which binds
both PR-A and PR-B (Onate et al., 1994). Labeled MMTV-PRE was incubated with
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purified PR-A, with U2 nuclear extract, with nuclear extract plus purified PR-A or with
nuclear extract plus purified PR-A and the PR monoclonal antibody. When U2 nuclear
extract alone was incubated with labeled MMTV-PRE, a diffuse nonspecific binding
complex was observed as a mobility-shift band which could not be abrogated or
supershifted by incubating with PR antibody. Purified PR-A alone did not bind to
labeled MMTV-PRE, as observed previously (Onate et al., 1994). However, in the
presence of 1 lig of nuclear extract, purified PR-A bound to labeled MMTV-PRE and
produced a strong mobility shift band which was supershifted with the PR antibody
(Figure 20A). These results are consistent with the previous observation (Onate et al.,
1994) that accessory proteins in the nuclear extract are required for PR to form functional
receptor complexes which bind to the PRE. Similar results were obtained when purified
PR-B was used instead of PR-A.
When PR-A protein in the absence of nuclear extract was tested for binding to the
BP5-PDRE oligodeoxynucleotide, it did not cause a band shift, which is similar to the
result obtained with the MMTV-PRE (Figure 20B). Incubation of labeled BP5-PDRE
with 5 p,g of U2 cell nuclear protein alone produced multiple shifted bands as shown in
Figure 18. When increasing amounts of purified PR-A were pre-incubated with nuclear
extract and then mixed with labeled BP5-PDRE, the intensity of bands I and 3
progressively decreased while the intensity of band 4 progressively increased
(Figure 20B). In contrast, when increasing amounts of purified baculovirus expressed
PR-B were incubated with 5 Rg of nuclear extract protein and labeled BP5-PDRE, the

110
gelshift pattern was not altered (Figure 21). This result is consistent with the previous
finding that overexpression of PR-A but not PR-B increased the magnitude of PG
dependent transactivation of the hIGFBP-5 promoter.
Addition of PR antibody together with PR-A and nuclear proteins did not alter the
gel shift pattern of labeled BP5-PDRE (Figure 20B), suggesting that either PR-A did not
participate in direct binding to BP5-PDRE or that the PR-A epitope to which the
PR-monoclonal antibody binds was masked by the nuclear proteins. As an alternative
approach to test whether PR-A bound directly to the BP5-PDRE sequence, the binding of
nuclear proteins to labeled BP5-PDRE was competed with excess amount of unlabeled
consensus MMTV-PRE DNA, which efficiently binds to PR-A in the presence of nuclear
extract (Figure 20A). If PR-A binds directly to BP5-PDRE, addition of excess unlabeled
MMTV-PRE DNA should efficiently compete with labeled BP5-PDRE in binding to
PR-A , reduce PR-A binding to BP5-PDRE and alter the band shift pattern. However,
addition of a 1000 fold molar excess of unlabeled MMTV-PRE to PR-A, nuclear
proteins, and labeled BP5-PDRE did not alter the gel shift pattern, further supporting the
conclusion that PR-A did not bind directly to BP5-PDRE.
To determine whether PR-A effects on U2 cell nuclear proteins were specific to
the proteins which bind to BP5-PDRE, we compared the effects of PR-A on gel shift
patterns of BP5-PDRE with effects on gel shift patterns of other responsive elements
(Sp 1 and TGF-B RCE). Labeled BP5-PDRE and labeled Sp 1 oligodeoxynucleotides
were each incubated with 5 gg of U2 nuclear extract in the presence of 0, 6, or 8 frnol of
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purified PR-A. Purified PR-A interacted with BP5-PDRE binding proteins and changed
•the mobility shift pattern of BP5-PDRE (Figure 21), but PR-A did not affect the mobility
shift pattern resulting from the binding of Sp 1 and other nuclear proteins to the labeled
•Spl oligodeoxynucleotide. Similarly, PR-A did not affect the mobility shift pattern
resulting from the binding of TGFB-RCE binding proteins to labeled TGFB-RCE
oligodeoxynucleotide. Thus among the response elements that were analyzed, the
interaction of PR-A with U2 cell nuclear factors is specific to BP5-PDRE binding
protein(s)
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Figure 15. Basal promoter activity of hIGFBP-5 promoter-reporter deletion
constructs. In this representative experiment, promoter-reporter constructs were
transiently transfected into U2 cells and incubated in DMEM supplemented with 10% CS
as described in Methods. CAT activity was normalized to 13-galactosidase activity from
respective groups and express as % of basal activity (cells transfected with pECAT1),
mean ± SD, n = 4 replicates.
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Figure 16. PG induction of promoter activity in hIGFBP-5 promoter-reporter
deletion constructs. The promoter-reporter constructs shown in Figure 3 were
transiently transfected into U2 cells along with phPR-A and pCMV13-gal as described in
Methods, and incubated in 2% CD-FBS. CAT activities were normalized to13galactosidase activities and expressed as % of respective control groups (cells transfected
with phPR-A and promoter-reporter construct incubated without PG), mean ± SD of at
least three independent experiments for each construct. There was no significant
difference in fold-induction of CAT expression by PG in groups pCAT753-pCAT162, as
determined by ANOVA. PG induction of CAT expression in the pCAT124 group was
significantly lower than in all other groups (p<.001).
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Figure 17. Mutation of CACCC boxes eliminates PG induction of hIGFBP-5
promoter activity. U2 cells were transfected with phPR-A, pCMVI3-gal and promoter
reporter constructs: pCAT162, pCAT162mut, pCAT162mDi, pCAT162mPr, or
pCAT124. Both CACCC box sequences at position -147 to -139 were mutated from
CCCACCCCCACCCC to AAAACCAAAACCCC in pCAT162mut. Only the distal
CACCC box was mutated to AAAACCCCCACCCC in pCAT162mDi and only the
proximal CACCC box was mutated to CCCACCAAAACCCC in pCAT162mPr. Cells
were incubated in 2% CD-FBS in the presence or absence of 10 nM PG. CAT activities
were normalized to B-galactosidase activities and expressed as % of respective control
group (transfected cells incubated in the absence of PG), mean ± SD of three independent
experiments. PG significantly increased CAT activities in pCAT162 and pCAT162mDi
transfected cells (p<.001) but did not significantly affect CAT activities in pCAT162mut,
pCAT162mPr or pCAT124 trassfected cells.
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Table 1 Sequence of oligodeoxynucleotides used as probes and/or competitors in EMSA
experiments

Oligonucleotide

Sequence

Gene

BP5-PDRE

5' - CCTCTCCCCACCCCCACCCCGTGTG- 3'
3' - GGAGAGGGGTGGGGGTGGGGCACAC -5 '

IGFBP-5

BP5-PDREml

5'-CCTCTCaaaACCaa4ACCCCGTGTG-3'
3 -GGAGAGt ttTGGtt t TGGGGCACAC - 5 '

Mutated
IGFBP-5

BP5-PDREm2

5'-CCTCTCCCaACCCCaACCWGTGTG-3'
3' GGAGAGGGtTGGGGt TGGGGCACAC - 5 '

Mutated
IGFBP-5

BP5-PDREm3

5'-CCTCTCCCaACCCCCACCCCGTGTG-3'
3'-GGTGTGGGtTGGGGGTGGGGCACAC- 5 '

Mutated
IGFBP-5

BP5-PDREm4

5' - CCTCTCCCCACCCgaACCCCGTGTG- 3 '
3' - GGTGTGGGGTGGGGtTGGGGCACAC- 3 '

Mutated
IGFBP-5

c-fos RCE (Robbin 5' - CGCGCCACCCCTCTGGCGCCACCGTG- 3'
3' GCGCGGTGGGGAGACCGCGGTGGCAG- 5 '
et al., 1990)

Human c-fos

TGF-13 RCE (Kim
etal., 1991)

5' CGCCCCCGGCCCCACCCCAGGAAG- 3
3' GCGGGGGCCGGGGTGGGGTCCTTC- 5'

Human TGF-f31

MNF (BasselDuby et al.., 1992)

5' -ACGCACAACCACCCCACCCCCTGTG- 3 '
3' - TGCGTGTTGGTGGGGTGGGGGACAC - 5 '

Ihunan
myoglobin

AP-2 (Williams, et
al. 1988)

5' -GATCGAACTGACCGCCCGCGGCCCGT - 3 '
3' - CTAGCTTGACTGGCGGGCGCCGGGCA- 5'

Metallothionein
-IIA

Spl (Brigg, et al.
1986)

5' -AATCGATCGGGGCGGGGCGAGC - 3 '
3' TTAGCTAGCCCCGCCCCGCTCG- 5 '

Simian Virus 40
early promoter

Underline indicates CACCC sequence. Lower case letter indicates mutated nucleotide.
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Figure 18. EMSA of BP5-PDRE binding to U2 cell nuclear factors. All
oligodeoxynucleotide sequences are shown in Table 1. A) 32P-labeled BP5-PDRE was
incubated with 3 gg of U2 cell nuclear extract as described in Methods in the absence
(lane b) or presence of a 50 fold molar excess of unlabeled BP5-PDRE (lane c), BP5PDREm1 mutant with six altered nucleotides in the CACCC boxes (lane d), consensus
AP-2 (lane e) and Spl (lane 0 sequences, and RCE sequences from TGFB and fos
promoters (lane g and h, respectively). Lane a shows the 32P-labeled BP5-PDRE in the
absence of nuclear extract. B) 32P-labeled BP5-PDRE was incubated with 3 jig of U2
nuclear extract in the absence (lane b) or the presence of 25, 50, and 100 fold molar
excess of unlabeled BP5-PDRE (lane c, d, and e, respectively), 25, 50, and 100 fold molar
excess of CACCC core sequence containing myocyte nuclear factor (MNF) binding
sequence from the human myoglobin promoter (lane f, g, and h, respectively), or 50 fold
molar excess of unlabelled BP5-PDRE CACCC box mutants. In BP5-PDREm2 (lane i),
both CACCC sequences are mutated to AACCC, in BP5-PDREm3 only the distal
CACCC sequence is mutated to AACCC and in BP5-PDREm4 (lane k) only the proximal
CACCC sequence is mutated.

Figure 19. BP5-PDRE binding factor(s) is an MNF-related transcription factor(s). Cold competition EMSA assay using
P-labeled BP5-PDRE was incubated with 3 jig
wild type BP5-PDRE, MNF, and AP-2 oligodeoxynucleotides as competitors. 32
of U2 nuclear extract in the absence (lane b) or the presence of 25 and 50 fold molar excess of unlabeled BP5-PDRE (lane c
and d), 25 and 50 fold molar excess of MNF binding sequence (lane e and 0, or 50 and 100 fold molar excess of AP-2
consensus sequence (lane g and h) prior to analysis by EMSA.

P-labeled consensus MMTV-PRE was
Figure 20. PR-A interaction with nuclear BP5-PDRE binding protein(s). A) 32
Incubated without proteins (lane a) or with I ps of U2 cell nuclear extract (lane b), 5 fmol of purified PR-A (lane c) or a
combination of nuclear extract and PR-A (lane d) prior to analysis by EMSA. Lane e is the same as lane d except 1 lig of PR
P-labeled BP5-PDRE was incubated with .5 lig of U2 cell nuclear
antibody, AB52, was added as described in Methods. B) 32
extract (lane a) in the presence of increasing amounts of PR-A (lane b-f). Numbers above each lane indicate fmol of PR-A. PR
antibody, AB52, was added to the mixture run in lane f.

P-labeled BP5-PDRE or Spl
Figure 21. The interaction between PR-A and BP5-PDRE binding protein(s) is specific. 32
oligonucleotide (indicated above lanes) were incubated with 5 lig of U2 cell nuclear extract (NE), with or without the addition
of purified PR-A (lane a-g) or PR-B (lane h-j) prior to analysis by EMSA. Numbers above each lane indicate fmol of purified
PR-A or PR-B. PR-A altered the gel shift pattern of BP5-PDRE but did not affect the gel shift pattern of Spl binding sequence.
PR-B did not affect the BP5-PDRE gel shift pattern.

CHAPTER THREE
IV. DISCUSSION
A. Effect of PG on IGF System Regulation of Bone Metabolic Processes
Clinical studies suggest that treatment of postmenopausal women with PG or
related progestagens reduces bone loss, either given alone or in combination with
estrogen (Abdalla et al.., 1985; Horowitz et al., 1993; Prior, 1990). However, the
mechanisms underlying PG protective effects on bone mass are =clear. When the
combination of progestagens and estrogen was given to postmenopausal women, there
was an increased serum alkaline phosphatase and osteocalcin, markers of bone
formation, more than effects of estrogen alone (Christiansen et al., 1985). In addition,
Grey et al. (1996) reported that combined estrogen and medroxyprogesterone therapy in
osteoporofic post-menopausal women resulted in a 65% greater increment in spinal bone
mineral density compared to unopposed estrogen treatment. Since it has been recently
demonstrated that the primary effect of estrogen is to inhibit bone resorption with very
minimal effect on bone formation (Mica et al.., 1992), the bone formation effect of the
combination treatment could, in part, be contributed to progestagens. Consistent with this
observation, it has been demonstrated in animal studies progestagen treatment alone
resulted in decreasing bone resorption and increasing bone formation as evidenced by
decreased a marker of bone resorption, urinary hydroxy praline, and increased alkaline
phosphatase and osteocalcin. (Barengolts et al., 1990; Kararnbolava et al., 1986; Snow
and Anderson, 1985).
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phosphatase and osteocalcin. (Barengolts et al., 1990; Karambolava et al., 1986; Snow
and Anderson, 1985).
In vitro studies have sought to determine mechanisms underlying PG effects on
bone formation. PG increased human osteoblast proliferation and differentiation (Lau et
al., 1994; Lempert et al., 1992; Tremollieres et al., 1992; Wei et al., 1993) transiently
increased IGF-II, type I , and type 2 IGF receptor mRNA levels in normal human bone
cells and increased the sensitivity of the cells to IGF-II stimulation of proliferation
(Lempert et al., 1992). In addition to increasing IGF-II and IGF receptor expression, PG
also alters the IGFBP expression pattern to further increase IGF activities in the
osteoblast Tnicroenvironment by decreasing expression of an inhibitory IGFBP, IGFBP-4,
and increasing expression of the stimulatory IGFBP, IGFBP-5.
Since PG increases IGF-II, and IGF-II increases IGFBP-5 production, it is
possible that PG increases IGFBP-5 expression indirectly by increasing IGF-II
production. However, when PG was added concomitantly with a protein synthesis
inhibitor, cycloheximide, we found that new protein synthesis was not required for PG
induction of IGFBP-5 mRNA levels. This result suggests that PG directly increases
IGFBP-5 mRNA levels by a mechanism that does not require increased IGF-II expression
and did not involve the increase in IGF-II expression. Furthermore, result of nuclear runon analysis demonstrate that PG directly increases IGFBP-5 gene transcription as early as
1 h.
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Since IGFBP-5, when added to osteoblast cell cultures, increased basal and IGF
stimulated proliferation (Andress and Birnbaum, 1991; Bautista et al., 1991; Kiefer et al.,
1991; Mohan et al., 1995), it is very likely that PG stimulation of human osteoblast
proliferation in vitro and the positive effects of progestagens on bone formation in vivo
•may be mediated, in part, by PG induction of IGFBP-5 production. The increase in
IGFBP-5 mRNA levels and subsequent increase in secreted IGFBP-5 protein in the
osteoblast microenvironrnent could result in an increase in IGF activities and increase in
osteoblast proliferation.

B. Comparison of the hIGFBP-5 Promoter to Other IGFBP Promoters
The human IGFBP-5 proximal promoter contained both CAAT and TATA boxes,
common elements of basal proximal promoters of many genes. Of six known human
IGFBP promoters, the IGFBP4 promoter is most like the hIGFBP-5 promoter in that it
also contains a CAAT box and a TATA box, at similar positions relative to the start of
transcription (Brinkman et al., 1988; Cubbage et al., 1989). in contrast, the human
IGFBP-3 (Cubbage et al, 1990) and rat IGFBP-4 (Gao et al., 1993) promoters contain a
TATA box between 37 to 40 bp from the transcription initiation site but do not contain a
CAAT box. No TATA or CAAT boxes were present in human or rat IGFBP-2 proximal
gene promoter regions (Binkert et al., 1992; Brown and Rechler, 1990). In contrast to
human IGFBP-1, -2, and -3, the human IGFBP-5 promoter gene does not contain a CpG
island.

130
More distal to the CAAT and TATA boxes, the human IGFBP-5 promoter
sequence contains several possible response elements that may mediate PG effects on
transcription. The consensus sequence for GRE/PRE is composed of two hexameric
half-site arranged as a palindrome with a 3 base pair spacer (GGTACANNNTGTTCT)
(Lieberman et al., 1993). None of the IGFBP promoters contain the perfect consensus
GRE/PRE sequence. The IGFBP-1 promoter is the only IGFBP promoter which contains
functional imperfect or nonconsensus GRE/PRE. The rat IGFBP-1 promoter contains a
single 15 bp GRE/PRE sequence (TGAACACGGGGATCC) (Goswami et al., 1994), and
the human IGFBP-1 also contains a similar 15 bp GRE/PRE sequence
(TGAACAAACAGGTCC) (Suwanichkul et al., 1994). Both GRE/PRE sequences bind
purified GR in DNA footprinting experiments and mutation of these GRE/PRE sequences
disrupts the effect of glucocorticoid induced IGFBP-1 gene transcription (Goswami et al..,
1994; Suwanichkul et al., 1994). Nine of the 12 nucleotides that comprise the 5'- and
3'- half-sites of the rat IGFBP-1 GRE/PRE sequence ( position -7 to -5 and position +2 to
+7) were identical to the human IGFBP-5 sequences identified as PRE-4 and PRE-5
(Figure 10). In contrast to the IGFBP-1 GRE/PRE, as shown by deletion analysis of the
hIGFBP-5 promoter, these putative PREs did not seem to function and were not required
for PG induction of hIGFBP-5 gene transcription. Instead, the 5'-flanking region
between -162 to -124 which contained CACCC sequences was required for the induction.
Comparison of the human IGFBP-5 promoter CACCC sequence in -162 to -124
to the corresponding reported rat (Zhu et al., 1993) and mouse IGFBP-5 sequences (Kou
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et al., 1994) (Figure 10) showed that this region was very well conserved among species,
suggesting that it may contain important elements required for transcriptional regulation
of the IGFBP-5 gene. Thus, it is possible that the results obtained from the studies of
these CACCC sequences in the hIGFBP-5 gene promoter will also apply to mouse and rat
IGFBP-5 promoters.

C. CACCC Sequences in the hIGFBP-5 Promoter and BP5-PDRE Binding
Protein(s)
From deletion and mutation analysis, the sequence responsible for PG induction
of hIGFBP-5 promoter activity was mapped to the CACCC box sequences between -124
and -162 and specifically to the proximal CACCC box. None of the putative PRE halfsites in the hIGFBP-5 proximal promoter is required for the induction. CACCC boxes
have been identified in the proximal promoters of other genes such as mouse and human
myoglobin (13assel-Duby et al., 1992; Blanchelot et al., 1992), muscle creatine kinase
(Horlick and Benfield, 1989), slow-cardiac troponin C (Parmacek et al., 1992),
tryptophan oxygenase (Schule et at, 1988), and erythroid B-globin (Weller et al., 1984).
Although CACCC boxes are present in several genes, the precise function of the CACCC
box sequences is still unknown.
A mechanism has been previously proposed for functional interaction between a
CACCC box and GRE/PRE in transactivation of a promoter by glucocorticoid. The
presence of a CACCC-box 15-39 bps from a consensus GRE/PRE in the tryptophan
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oxygenase promoter enhanced GR/PR binding to the GRE/PRE and stimulated gene
transcription (Schule et al., 1988). Mutation of the CACCC box abolished this synergism
(Schule et al., 1988). Because the hIGFBP-5 promoter CACCC box is in close proximity
to imperfect GRE/PRE sequences, it is possible that transacting factors binding to the
CACCC box interacted with PR and synergized with PR to induce hIGFBP-5 gene
transcription. However, deletion analysis of the hIGFBP-5 promoter showed that the
same fold induction of the hIGFBP-5 promoter was obtained when cells were transfected
with either pCAT252, which contained PRE-4, PRE-5 and CACCC boxes, or pCAT162
which contained only the CACCC boxes. Thus, there is no evidence supporting an
interactive mechanism between the putative PREs and CACCC box in the hIGFBP-5
promoter.
Since deletion and mutation analysis showed the proximal CACCC box in the
hIGFBP-5 promoter is required for PG transactivation, experiments were done to
determine what type of transcription factor proteins might bind to the CACCC box.
EMSA with U2 cell nuclear extract and labeled BP5-PDRE demonstrated several
protein-DNA complexes. Several CACCC sequences previously identified in other gene
promoters were compared to the hiGFBP-5 CACCC box by EMSA. Since a CACCC
box sequence containing retinoblastoma control element (RCE) motif has been identified
as an important sequence conferring RB-mediated regulation of gene expression (Kim et
al., 1992; Kim et al., 1991; Kim et al., 1992; Pietenpol et al., 1991; Robbin et al., 1990;
Yu et al., 1992), it is possible that BP5-PDRE binding proteins could be RCE binding
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proteins. To assess whether the factor(s) binding to the CACCC sequence (BP5-PDRE)
might be similar to RCE binding factors, two RCE oligodeoxynucleotides with sequences
similar to but distinct from CACCC sequences (Table 1) were used in cold-competition
experiments. None of the RCE oligodeoxynucleotides tested was as effective as the wild
type BP5-PDRE in competing for the trans-acting factors which bound to BP5-PDRE.
Therefore, it is unlikely that the BP5-PDRE binding factor is an RCE binding protein.
In addition to RCE binding factors, CACCC sequences may be bound by
members of the Spl family (Spl, Sp2 and Sp3) or AP-2, ubiquitous DNA binding
factors that activate transcription (Faisst and Meyer, 1992; Kim et al., 1992; Kingsley and
Winoto, 1992). Recently, Kinsley and Winoto (1992) demonstrated that members of the
Spl family, Sp2 and Sp3, bind strongly to the Spl binding site. Therefore, to determine
whether BP5-PDRE binding protein was AP-2 or a member of the Spl family, consensus
AP-2 and Spl DNA sequences were used in cold-competition EMSA. Although Spl
oligodeoxynucleotide partially competed for the binding with bands 1 and 3 and AP-2
oligodeoxynucleotide partially competed for binding with band 3 (Figure 18), both
consensus oligodeoxynucleotides still were less effective as wild-type BP5-PDRE
oligodeoxynucleotide in partially competing for binding with BP5-PDRE binding
protein(s). Thus, the results suggest that BP5-PDRE binding protein(s) were not AP-2 or
members of the Spl family.
The sequence CCCACCCC which confers PG responsiveness in the hIGFBP-5
promoter was identical to the binding sequence of myocyte nuclear factor (MNF) in
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human myoglobin promoter (Bassel-Duby et al., 1994). MNF is a novel winged-helix
(FINF-3/fork head) transcription factor which interacts with other factors such as
myocyte-specific enhancer binding factor 2 (MEF-2) to confer muscle-specific
transcription to the human myoglobin promoter (Bassel-Duby et al., 1992). MNF
expression is increased during myocyte differentiation (Bassel-Duby et al., 1994). To
determine whether the BP5-PDRE binding protein could be MNF, MNF binding site
oligodeoxynucleotides were used in cold-competition EMSA. Unlabeled wild type
BP5-PDRE oligodeoxynucleotide sequence as low as 25 fold molar excess completely
competed for the proteins which bound to the labeled BP5-PDRE whereas the MNF
binding-site oligodeoxynucleotide required up to 50 fold molar excess for effective
competition. In contrast, the AP-2 consensus oligodeoxynucleotide sequence as high as
100 fold molar excess was not effective in competing for binding (Fig= 19). Thus,
among all the consensus binding sites tested, the MNF binding site
oligodeoxynucleotide was the best competitor for binding to the BP5-PDRE binding
protein(s), suggesting that BP5-PDRE binding proteins may be most closely related to
MNF.
Interestingly, IGFBP-5 is abundantly expressed in muscle cells in the developing
embryo and during terminal differentiation of several myogenic cell lines (James et al.,
1993). By transfecting deletion promoter-reporter constructs of the mouse IGFBP-5
promoter into C2I myoblast cells, Rotwein et al. (1995) demonstrated that the proximal
156-bp fragment, which containsthe same CACCC box sequences as in hIGFBP-5
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promoter, is responsible for the differentiation dependent rise in IGFBP-5 gene
transcription. Based on sequence homology and the importance of this sequence for the
expression of IGFBP-5 in muscle cells during differentiation, Rotwein et al. (1995)
suggested that MNF bound to these CACCC boxes. However, the results from our cold
competition studies suggest that BP5-PDRE binding proteins or CACCC binding proteins
were not identical to MNF since wild type BP5-PDRE oligodeoxynucleotide competed
better than MNF oligodeoxynucleotide for binding. Although MNF is unlikely to be the
BP5-PDRE binding protein(s), it is possible that BP5-PDRE binding proteins could be
MNF-related transcription factors since both IGH3P-5 and I expression were induced
during myocyte differentiation and among all the CACCC sequences tested the
MNF-oligodeoxynucleotide competed most effectively for binding to the labeled
BP5-PDRE oligodeoxynucleotide.
Since both proximal and distal CACCC boxes of the BP5-PDRE sequences were
very similar, it is interesting to speculate that both CACCC boxes could interact with
BP5-PDRE binding proteins. However, according to mutation analysis, only the
proximal CACCC box was required for the binding of BP5-PDRE binding proteins, and
for transactivation of the promoter by PG. This may be due to differences in the proximal
flanking region in each box which could influence the binding of BP5-PDRE binding
proteins. Bassel-Duby et al. (1992) demonstrated that mutation of the MNF binding site
flanking sequence had a minimal effect on promoter activity. This suggested that MNF
site flanking sequences had very little influence on the binding of MNF. Since the results
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from cold competition assays suggested that BP5-PDRE binding factors could be MNF or
a related transcription factor, it is possible to speculate that the flanking region of the
CACCC box in hIGFBP-5 gene has a minimal effect on the binding of the BP5-PDRE
binding protein to the CACCC box. Alternatively, mutation of each CACCC box could
cause different changes in DNA secondary structure and influence the ability of proteins
to bind to the BP5-PDRE binding protein. The mutation of the proximal CACCC box,
which abolished the binding of BP5-PDRE binding proteins, may result in DNA
secondary structures which are unfavorable for binding to the BP5-PDRE binding
proteins.

D. Interaction of Steroid Hormone Receptors with Other Transcription Factors
Classically, ligand-activated steroid hormone receptors stimulate gene
transcription through direct binding to consensus hormone responsive elements (HREs)
(Rories and Spelberg, 1989). Unactivated steroid hormone receptors in vivo have either
neutral or silencing activity in the absence of ligand. Upon binding to the hormone, the
receptor becomes a positive regulator. In the absence of hormone, PR and GR have been
shown to exist as 8-10 S complexes associated with heat-shock proteins (hsp90, hsp70,
and hsp56) (Georgopoulus and Welch, 1993; Hendrick and Hartl, 1993; Kost et al.,
1989). Upon binding ligand to the receptor, heat-shock proteins dissociate, receptors
dimerize, and the actual receptor dimers bind to specific hormone response element
(HRE) DNA sequences and transactivate target genes (Tsai and O'Malley, 1994). The
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removal of the heat shock protein, however, is not sufficient by itself to convert a steroid
receptor from hormone-dependency to one that is constitutively active (Bagchi et al.,
1991). Using a hormone-dependent, cell free system and purified receptor, Bagchi et a
(1991) demonstrated that receptor binding to DNA and transactivation of a target gene,
requires the binding of hormone to the receptor even in the absence of heat shock protein.
One explanation for this hormone requirement for receptor activation is that a
conformational change is induced in the receptor by the hormone. Supporting this
conclusion, EMSA studies have shown that hormone binding alters the gel shift pattern of
purified steroid receptor-DNA complexes (Beekman et al., 1993). Using protease
digestion and monoclonal antibody mapping to detect ligand-dependent conformational
changes, Allan et al. (1992) showed that PG induces a conformational change in PR,
converting the entire hormone-binding domain to a very compact structure.
The results of our studies suggest that PR mediated induction of the hIGFBP-5
gene did not involve direct binding of PR-A to PRE. The region responsible for PG
responsiveness was mapped to a CACCC box. It is possible that binding of PR-A to the
CACCC box stimulated hIGFBP-5 gene transcription. In support of this possibility,
recent studies suggest that steroid hormone receptors stimulate gene transcription by
mechanisms which are independent of direct binding to consensus HREs (Kutoh et al.,
1992; Miner and Yamamoto, 1991; Norris et al., 1995; Sukovich et al., 1994). The
receptors could activate gene transcription through novel DNA sites that differ
substantially from the consensus HREs (Norris et al., 1995; Schweers et al., 1990;
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Sukovich et al., 1994). Using a genetic selection system in yeast, Norris et al.(1995)
identified a new subclass of Alu family DNA repeats in the BRCA-1 gene which
functions as an estrogen receptor-dependent enhancer and confers receptor-dependent
estrogen responsiveness to a heterologous promoter. in addition, Sukovich et al. (1994)
identified a TA-rich sequence and a CCAAT sequence which were crucial for induction
of the brain creatine Idnase (BCK) promoter by the estrogen receptor. However, direct
binding of ER to the sequences is not required for transactivation. Using deletion and
mutation analysis, Schweers et al. (1990) identified steroid dependent regulatory elements
(SDREs) in the ovalbumin promoter which did not have sequence homology to any of the
consensus HREs. The SDREs conferred hormone (estrogen, glucocorticoid, progesterone
and dihydroxytestosterone) responsiveness to the ovalbumin gene but did not bind to
partially purified progesterone receptor. Since direct binding of the receptor to
nonconsensus HREs is not required, it is, therefore, possible that the conformational
changes induced by hormone binding allow the activated receptors to interact with other
factors which bind to the nonconsensus HREs to activate transcription.
Analysis of the hiGFBP-5 promoter suggests that purified PR-A does not bind to
the functional CACCC box but interacts with proteins or protein complexes bound to the
CACCC box. Therefore, it is likely that ligand activated PR-A stimulates hIGFBP-5
gene transcription indirectly via interaction with transcription factors or cofactors which
bound to the CACCC box. Supporting this conclusion, multiple factors have been
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described which interact with steroid hormone receptors in a ligand-dependent manner
and modulate receptor activities. These factors can be grouped into three categories:
(1) other nuclear transcription factors, (2) nuclear factors which are required for efficient
DNA binding by steroid hormone receptors ,and (3) transactivating function intermediary
factors (11Fs) which mediate the transcription activation function of the steroid hormone
receptor to the basal transcription machinery. The three types of factors are discussed in
the following paragraphs.
Steroid hormone receptors have been shown to bind to other nuclear transcription
factors. Interactions of PR, GR and androgen receptor (AR) with AP-1 (Fos and Jun)
components downregulate transcription of target genes (Jong et al., 1990; Schule et al.,
1990; Yang-Yen et al., 1990). Yang-Yen et al. (1990) showed that interaction of GR
with AP-1 resulted in a complex that was unable to bind to DNA. Others have proposed
that, depending on the relative composition of Jun and Fos, GR receptor activity can
either be enhanced or inhibited (Shemshedini et al., 1991). These studies not only
demonstrated that the binding of nuclear transcription factors to steroid hormone
receptors modulate the receptor activities, they also showed the existence of the crosstalk
between ligand-activated and phosphorylation-regulated pathways conferred by AP-1 at
the nuclear level.
Nuclear factors which enhance the DNA binding of the steroid hormone receptors
have been described. Two nonhistone chromosomal proteins that can bind to the spacer
of palindromic EREs were shown to enhance ER binding (Fawell et al., 1990). In
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addition, in vitro binding of highly purified human ER to an ERE requires the addition of
single-stranded-DNA-binding proteins (Mulcherjee and Chambon, 1990). Cavanaugh and
Simmon Jr. (1990) showed that a 93-1cDa protein increased binding of activated GR to
nuclei and chromatin in an ATP-dependent manner. Edwards et al. (1989) showed that
the maximum binding of PR to PREs in vitro was dependent upon both hormone and a
nonreceptor nuclear factor (Edwards et al., 1989). Recently, Onate et al. (1994)
demonstrated that the high-mobility-group chromatin protein (1MG-1) enhances the
binding of both activated PR-A and PR-B to an MMTV-PRE by inducing a structural
change in the target DNA.
In many studies overexpression of one receptor results in the squelching of its
own or another receptor's activity McDonnell et al., 1994; Meyer et al., 1989; Vegato et
al., 1993; Wen et al., 1994). Furthermore, the functional activities of various
transactivation domains of the ER vary in the context of different cell types (Shemshedini
et al., 1992) which suggests that the target for various activation domains may be distinct.
Since the basic transcription machinery exists in all genes, it is possible that factors other
than general transcription factors, such as coactivators or transactivation function
intermidiatory factors (TIFs), could play an important role in receptor activation. Several
receptor associated TIFs have been identified. Shemshedini et al. (1992) have identified
a TIF that eliminated the self-squelching effect of the estrogen receptor (ER) but had no
influence on basal transcription. ER associated proteins ERAP160 (Halachmi et al.,
1994), RIP160 and RIP80 (Cavailles et al., 1994) exhibit estradiol-dependent binding to
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the ER. The binding of these ER associated proteins to the ER correlates with the ability
of the ER to activate transcription in vivo. Recently, several authors used a yeast-based
genetic system to demonstrate that several factors including SW11, SWI2, SWI3, SIN3
and SPT6 (Baniahmad et al., 1995; Nawez et al., 1994; Yoshinaga et al., 1992) enhance
the transcriptional activity of different steroid hormone receptors. Using a yeast twohybrid system, Onate et al. (1995) identified a protein, steroid receptor coactivator-1
(SRC-1), which interacts with and enhances transactivation of steroid hormone receptors.
Coexpression of SRC-1 reversed the ability of the estrogen receptor to squelch activation
of PR (Onate et al., 1995). These coactivators were proposed to bridge receptors to the
core transcription machinery which is consistent with the notion that multiple accessory
factors are involved in receptor transactivation.
Several steroid hormone receptors including PR (Klein-Hitpass et al., 1990), ER
(Elliston et al., 1992) and GR (Tsai et al., 1990) stabilize the formation of preinitiation
complexes on DNA; however the precise mechanism is still unclear. In addition to
interaction with TIF proteins, hormone receptors (COUP-TF, ER and PR) interact in vitro
with the basal transcription factor, TFIIB (Ing et al., 1992). Since TFIIB has been
reported to be a rate-limiting component of trancriptional activation (Lin and Green,
1991), Ing et al.(1992) proposed that binding of a steroid hormone receptor to its HRE
recruits TFIIB into the initiation complex and stabilizes the complex. This stable
complex allows subsequent binding of RNA polymerase II and other general transcription
factors TFIIF, E, H and J to efficiently complete the formation of the preinitiation
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complex and rapidly transcribe an activated gene. Consistent with these findings, VP-16,
a viral transactivator, activates transcription by interacting with TFIIB (Roberts et al.,
1993).

E. Proposed Mechanisms of PG Induction of hIGFBP-5 Gene Transcription
PG induction of hIGFBP-5 gene transcription is quite unique in that it is mediated
through PR-A and not PR-B. In most PG inducible genes that have been examined,
transcription is increased by binding of ligand-activated PR-B to a PRE within the gene
promoter. To date, the only known example of a gene that is activated by PR-A and not
PR-B is the chicken ovalbumin gene (Schweers et al., 1990), however, the detailed
mechanism for this interaction was not determined. PR-A and PR-B are likely to mediate
transcriptional regulation through different mechanisms because hPR-A in many cases
functions as a dominant negative regulator and does not bind directly to an HRE (bra et
al., 1988; Vegato et al.., 1993). PR-A has been proposed to act by binding in a
nonproductive manner to a limiting cofactor protein that is required for activation of other
steroid hormone receptors (Tung et al., 1993; Vegato et al., 1993). However, in contrast
to other systems, we found that PR-A functioned as an activator of hIGFBP-5 gene
transcription.
interestingly, PR-A and PR-B differ only in the length of their N-terminus but yet
they have different functional properties. It is possible that loss of 164 amino acid
residues at the N-terminus of PR-A could result in a different folding structure compared
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to PR-B. In addition, Beck et al demonstrated that both isoforms exhibit significant
amounts of phosphorylation and undergo an increase in phosphorylation upon hormone
stimulation (Beck et al., 1992). PR-A has fewer phosphorylation sites compared to PR-B
(personal commumication, Dean P. Edwards). Both different folding and changes in
phosphorylation sites could cause PR-A to function differently from PR-B by interacting
with different sets of proteins or transcription factors.
There are at least three possible mechanisms by which PR-A could mediate
transactivation of the hIGFBP-5 gene. Regarding the classical mechanism of PG
induction of gene transcription, activated PR dimerize, bind to the consensus PRE, and
activate gene transcription. However, PREs half-sites in the hIGFBP-5 gene 5'-flanking
region from -753 and +23 were not functional. Although PR does not bind effectively to
PRE half sites, clusters of GRE/PRE half-site have been shown to bind to the receptor
and mediate ligand dependent transactivation through a synergistic interaction between
the multiple half-sites (Bailly et al., 1986; Beato et al., 1989; Lieberman et al., 1993). As
shown in Figure 16, deletion of all PRE half-sites present in the hIGFBP-5 5'-flanking
region in pCAT162 conferred PG responsiveness. According to the data presented, the
induction of the hIGFBP-5 gene by PG did not involve a PRE or PRE half-site; therefore,
it is unlikely that the transactivation follows a classical mechanism.
Since no PRE or PRE half-site is involved and a CACCC sequence is implicated
in PG induction of hIGFBP-5 gene transcription, it is possible that the CACCC sequence
binds to a negative regulator(s) or transcriptional repressor(s) which suppresse gene
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transcription. In the presence of PG, the activated PR interacts with and removs the
repressor(s) from the CACCC sequence, causing an increase in hIGFBP-5 gene
transcription. Therefore, deletion of the CACCC box abolishing binding of CACCC
binding proteins should increase gene transcription. However, deletion or mutation of
both CACCC boxes did not cause any changes in basal promoter activity. Thus, the data
argues against the possibility that a transcriptional repressor(s) binds to the functional
CACCC sequences.
EMSA analysis shows there are at least five distinct protein-DNA complexes
based on size, suggesting that the CACCC boxes interacted with proteins of different
sizes or with different protein complexes. Although it remains to be determined whether
CACCC box binds to individual proteins or protein complexes, there is considerable
evidence supporting the notion that protein complexes bind to CACCC boxes. Several
transcription factors such as the Sp 1 family, AP-2, RCE-binding proteins, and MNF have
been shown to bind to CACCC sequences (Bassel-Duby et al., 1992; Faisst and Meyer,
1992; Kim et al., 1992). However, the activity of the most CACCC binding proteins is
regulated by binding of other transcription factors (Bassel-Duby et al., 1992; Kim et al.,
1992). In the case of MNF which could be the BP5-PDRE binding protein or related to
it, Bassel-Duby et al suggested that MNF is likely to require protein-protein interactions
with other heterologous transcription factors such as MEF-2, which does not bind to the
MNF binding sequence, for efficient transactivation in muscle cells (Bassel-Duby et al.,
1992). Thus, it is very likely that BP5-PDRE binding proteins bind other transcription
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factors which modulated their activities. in support of this conclusion, a CACCC box is
required for efficient and accurate gene transcription in several genes (Bassel-Duby et
al., 1992; Direks et al., 1983). Thus, proteins interacting with CACCC binding proteins
may influence the efficiency of gene transcription.
As shown in Figure 20, PR-A caused the disappearance of at least two
DNA-protein complexes and the appearance of at least one DNA-protein complex,
suggesting that PR-A interacts with the CACCC or BP5-PDRE binding protein complex.
In addition, direct binding of purified PR-A to labeled BP5-PDRE was not observed,
suggesting that PR-A interacts with BP5-PDRE binding protein complexes rather than
with BP5-PDRE DNA sequences. Several recent reports indicate that PR-A, in
particular, interacts with limiting cofactors required for activation of other steroid
hormone receptors (Twig et al., 1993; Vegato et al., 1993; Wen et al., 1994).
Evidence from our studies and others supports the hypothesis that BP5-PDRE
binds to protein complexes which consist of CACCC binding protein(s) and other
transcription factors. These factors may or may not bind directly to the CACCC box or
flanking sequences. However, in the presence of ligand-activated PR-A, PR-A interacts
with components of the BP5-PDRE binding protein complexes, removes the factors
critical to the complex, and allowes other transcription activators to bind to the
complexes and activate hIGFBP-5 gene transcription. A schematic representation of this
model is shown in Figure 22.
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Figure 22. Proposed novel molecular mechanism of PG action. A) Classical
mechanism of PG action. Upon binding to PG, PRs undergo transformation and become
activated PRs. Activated PRs (oval shape) then homodimerize, bind to PRE and activate
gene transcription. B) Proposed novel molecular mechanism of PG action. In basal
conditions before PG activation, transcription factors (hexagonal shape) bind to CACCC
binding proteins and prevent transcription activators (pentagonal shape) from binding to
CACCC binding proteins. Upon activation, activated PRs interact and form complexes
with the inhibitory transcription factors and allow transcription activators to bind to
CACCC binding proteins and activate gene transcription. In contrast to the classical
model, activated PRs do not bind directly to the DNA elements, the CACCC boxes.
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F. Conclusion
The studies presented here demonstrate that PG-induces an increase of steady
state hIGFBP-5 mRNA primarily through a transcriptional mechanism. The significance
of this study is that the element responsible for PG responsiveness was mapped to a
CACCC sequence instead of a classical PRE. In contrast to our current understanding of
PR activated gene transcription which involves the direct binding of PR to a PRE, our
results suggested a novel mechanism of PG mediated transcriptional regulation. Direct
DNA binding of a ligand-activated PR to the BP5-PDRE did not occur. Instead,
activated PR-A interacts with BP5-PDRE binding proteins. To our knowledge, this is the
first report of a mammalian gene in which transcription is activated by PR-A and not
PR-B. The finding that PR-A, and not PR-B, interacts with other transcription factors or
cofactors which bind to BP5-PDRE may help explain differences in the promoter and cell
type specificity of PR-A and PR-B mediated gene transcription.

G. Future Directions
Although PR-A is structurally very similar to PR-B (PR-A lacks 164 amino acids
at the N-terminus), the two receptor isoforms function differently. Studies defining the
•role of the first 164 amino acid region in the functional differences of the two PR
isoforms will be informative. As mentioned earlier, there are at least two possible
differences in the PR-A which might cause PR-A to interact with different sets of
proteins: (1) the tertiary structure of PR-A may be different from PR-B, and (2) there are
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fewer phosphorylation sites in PR-A. Since it is technically more feasible to test the •
second possibility, studies should be carried out to test this possibility. PR-B mutants
will be used in which all phosphorylation sites within first 164 amino acids of the
N-terminus are mutated. The mutated PR-B expression vector will be cotransfected with
pCAT162 into U2 cells. The transfected cells will then be treated with PG for 24 h and
CAT activity will be assayed. pCAT162 will be used since this construct contains the
minimal promoter required for PG responsiveness. If mutant PR-B can activate
hIGFBP-5 gene transcription but wild type PR-B cannot, then it is likely that the
phosphorylation sites in PR-B prevent the receptor from interacting with appropriate
proteins required to activate hIGFBP-5 gene transcription. If mutant PR-B fails to
activate hiGFBP-5 gene transcription, then it is more likely that differences in the tertiary
structure of PR-B and PR-A account for PR-A activating hIGFBP-5 gene transcription.
A series of N-terminal deletions of PR-B could be made to progressively remove parts of
the PR-B N-terminal sequences.
We have established that BP5-PDRE binding proteins bind to the CACCC boxes;
however, further studies should be carried out to determine the significance of the
flanking region of the functional CACCC boxes. First one should determine which
nucleotides mediate BP5-PDRE binding using DNA footprinting analysis. This analysis
will provide a picture of the nucleotides required for binding of BP5-PDRE binding
proteins. Once the region required for binding is established, mutation analysis of the
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CACCC box flanking region or the binding region will be carried out to verify the
findings from DNA footprinting analysis.
Based on results obtained from this study, we propose that PR-A activates
hIGFBP-5 gene transcription via a novel mechanism by which ligand-activated PR-A
interacts with other transcription factors or cofactors in the BP5-PDRE protein complexes
allowing a transcription activator to bind to the complexes and activate hIGFBP-5 gene
transcription. It remains to be established whether BP5-PDRE DNA sequences interact
with individual proteins or protein complexes. One can use preparative scale EMSA to
determine how many proteins are in one DNA-protein complex by cutting the band
representing each DNA-protein complex and analyzing the composition of the protein
complex on a denaturing protein gel.
One of the most compelling studies which should be carried out is to determine
the identity of the BP5-PDRE binding factors which interact with PR-A. Since PR-A
acts as a dominant negative repressor of several steroid hormone receptors, several
investigators have proposed that PR-A interacts with limiting factor(s) required for the
activation of steroid hormone receptors (Tung et al., 1993; Vegato et al., 1993; Wen et
al., 1994). To date only one cofactor has been demonstrated to interact with hPR. Using
the yeast tv1/4/z) hybrid system with the hPR ligand-binding domain as the bait, Onate et al.
(1995) isolated a protein called steroid receptor coactivator-1 (SRC-1) which interacts
with hPR. Coexpression of SRC-1 with either PR, OR, ER, TR, or RXR enhances the
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activity of all of the receptors tested. It would be interesting to test whether SRC-1 could
interact with BP5-PDRE binding proteins or PR-A by using EMSA.
The yeast two hybrid system can be used to isolate protiens in U2 cells which
interact with hPR-A. One can use the yeast two hybrid system with hPR-A cloned into a
vector containing the GAL-4 DNA binding domain and a library of cDNAs encoding
proteins expressed in U2 cells cloned into a vector containing GAL-4 activation domain.
The interaction between the factors and hPR-A in vivo will reconstitute the GAL4
transcription activator function and will result in transcription of the reporter gene.
After the cDNA encoding factors interacting with PR-A have been cloned, further
studies to identify factors which are involved in PG activation of hIGFBP-5 gene
transcription should be carried out. Since we propose that PR-A removes factors which
blocked the binding of transcriptional activators, overexpressing such factors which
interacts with PR-A should abolish PR-A's ability to activate hIGFBP-5 gene
transcription. Since PR-A has been proposed to function in a cell- and promoter- specific
manner (Tora et al., 1988), it will be important to investigate the expression pattern of
these factors in different cell types to gain more understandings of how PR-A functions in
those cells.
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